<article title='Amphetamine'><paragraph><template><target>featured article</target></template><template><target>bots</target><arg name="deny">KasparBot,Citation bot</arg></template><space/><template><target>about</target><arg>mixtures of [[levoamphetamine]] and [[dextroamphetamine]]</arg><arg>other uses</arg></template><template><target>pp-semi-indef</target><arg name="small">yes</arg></template><template><target>Use dmy dates</target><arg name="date">April 2015</arg></template><template><target>Infobox drug</target><arg name="Watchedfields"><space/>
</arg><arg name="Verifiedfields"><space/>
</arg><arg name="verifiedrevid"><space/>629722425
</arg><arg name="drug_name"><space/>Amfetamine ({{abbr|INN|International Nonproprietary Name}})
</arg><arg name="IUPAC_name"><space/><center>(''RS'')-1-phenylpropan-2-amine</center>
</arg><arg name="image"><space/>Racemic amphetamine 2.svg
</arg><arg name="alt"><space/>An image of the amphetamine compound
</arg><arg name="image2"><space/>D-Amphetamine-3D-balls.png
</arg><arg name="alt2"><space/>A 3d image of the D-amphetamine compound
</arg><arg name="imagename"><space/>1 : 1 mixture (racemate)

<space/></arg><arg name="pronounce"><space/>{{IPAc-en|audio</arg><arg name="Drugs.com"><space/>{{Drugs.com|parent|amphetamine}}
</arg><arg name="pregnancy_US"><space/>C
</arg><arg name="legal_AU"><space/>Schedule 8
</arg><arg name="legal_CA"><space/>Schedule I
</arg><arg name="legal_DE"><space/>Anlage III
</arg><arg name="legal_NZ"><space/>Class B
</arg><arg name="legal_UK"><space/>Class B
</arg><arg name="legal_US"><space/>Schedule II
</arg><arg name="legal_UN"><space/>Psychotropic Schedule II
</arg><arg name="legal_status">
</arg><arg name="licence_US"><space/>Amphetamine
</arg><arg name="dependency_liability"><space/>[[Physical dependence|Physical]]: none<br />[[Psychological dependence|Psychological]]: moderate
</arg><arg name="addiction_liability"><space/>Moderate
</arg><arg name="routes_of_administration"><space/>Medical: [[Oral route|oral]], [[Nasal administration|nasal inhalation]]<space/><br />Recreational: [[Oral route|oral]], [[Nasal administration|nasal inhalation]], [[Insufflation (medicine)|insufflation]], [[Suppository|rectal]], [[intravenous]]

<space/></arg><arg name="bioavailability"><space/>Rectal&nbsp;95–100%; {{nowrap|Oral 75–100%}}<ref name</arg><arg name="protein_bound"><space/>15–40%<ref name</arg><arg name="metabolism"><space/>Amphetamine only:<br />[[CYP2D6]],<ref name</arg><arg name="metabolites"><space/>{{nowrap|[[4-hydroxyamphetamine]]}}, {{nowrap|[[4-hydroxynorephedrine]]}}, {{nowrap|[[4-hydroxyphenylacetone]]}}, [[benzoic acid]], [[hippuric acid]], [[norephedrine]], [[phenylacetone]]<ref name</arg><arg name="onset"><space/>{{abbr|IR|Immediate release}} dosing: Immediate<br />{{abbr|XR|Extended release}} dosing: 1.5–2&nbsp;hours<ref name</arg><arg name="elimination_half-life"><space/>{{abbr|D-amph|Dextroamphetamine}}:9–11&nbsp;hours<ref name</arg><arg name="duration_of_action"><space/>{{abbr|IR|Immediate release}} dosing: 3–7&nbsp;hours<ref name</arg><arg name="excretion"><space/>Primarily [[renal]];<br />[[pH]]-dependent {{nowrap|range: 1–75%}}<ref name</arg><arg name="CAS_number_Ref"><space/>{{cascite|correct|CAS}}
</arg><arg name="CAS_number"><space/>300-62-9
</arg><arg name="ATC_prefix"><space/>N06
</arg><arg name="ATC_suffix"><space/>BA01
</arg><arg name="ChEBI_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEBI"><space/>2679
</arg><arg name="PDB_ligand"><space/>FRD
</arg><arg name="IUPHAR_ligand"><space/>4804
</arg><arg name="StdInChI_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChI"><space/>1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
</arg><arg name="StdInChIKey_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChIKey"><space/>KWTSXDURSIMDCE-UHFFFAOYSA-N
</arg><arg name="PubChem"><space/>3007
</arg><arg name="DrugBank_Ref"><space/>{{drugbankcite|correct|drugbank}}
</arg><arg name="DrugBank"><space/>DB00182
</arg><arg name="ChemSpiderID_Ref"><space/>{{chemspidercite|correct|chemspider}}
</arg><arg name="ChemSpiderID"><space/>13852819
</arg><arg name="NIAID_ChemDB"><space/>018564
</arg><arg name="UNII_Ref"><space/>{{fdacite|correct|FDA}}
</arg><arg name="UNII"><space/>CK833KGX7E
</arg><arg name="KEGG_Ref"><space/>{{keggcite|correct|kegg}}
</arg><arg name="KEGG"><space/>D07445
</arg><arg name="ChEMBL_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEMBL"><space/>405
</arg><arg name="synonyms"><space/>α-methylphenethylamine

<space/></arg><arg name="C">9<space/></arg><arg name="H">13<space/></arg><arg name="N">1
</arg><arg name="molecular_weight"><space/>135.20622&nbsp;g/mol<ref name</arg><arg name="smiles"><space/>NC(CC1</arg><arg name="InChI"><space/>1/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
</arg><arg name="density"><space/>0.9±0.1
</arg><arg name="boiling_point"><space/>203
</arg><arg name="boiling_notes"><space/>at 760&nbsp;[[Millimeter of mercury|mm&nbsp;Hg]]<ref name</arg><arg name="melting_point"><space/>11.3
</arg><arg name="melting_notes"><space/>(predicted)<ref name</arg></template></paragraph><paragraph><bold>Amphetamine</bold>#tag:ref (contracted from<space/><template><target>nowrap</target><arg>[[Alpha and beta carbon|alpha]]‑[[methylphenethylamine]]</arg></template>) is a<space/><link><target>Potency (pharmacology)</target><part>potent</part></link><space/><link><target>central nervous system</target></link><space/>(CNS)<space/><link><target>stimulant</target></link><space/>that is used in the treatment of<space/><link><target>attention deficit hyperactivity disorder</target></link><space/>(ADHD),<space/><link><target>narcolepsy</target></link>, and<space/><link><target>obesity</target></link>. Amphetamine was discovered in 1887 and exists as two<space/><link><target>enantiomer</target><trail>s</trail></link>:#tag:ref<space/><link><target>levoamphetamine</target></link><space/>and<space/><link><target>dextroamphetamine</target></link>.<space/><italics>Amphetamine</italics><space/>properly refers to a specific chemical, the<space/><link><target>racemic</target></link><space/><link><target>free base</target></link>, which is equal parts of the two enantiomers, levoamphetamine and dextroamphetamine, in their pure amine forms. However, the term is frequently used informally to refer to any combination of the enantiomers, or to either of them alone. Historically, it has been used to treat nasal congestion, depression, and obesity. Amphetamine is also used as a<space/><link><target>performance enhancer</target><part>performance</part></link><space/>and<space/><link><target>Nootropic</target><part>cognitive enhancer</part></link>, and recreationally as an<space/><link><target>aphrodisiac</target></link><space/>and<space/><link><target>euphoriant</target></link>. It is a<space/><link><target>prescription medication</target></link><space/>in many countries, and unauthorized possession and distribution of amphetamine are often tightly controlled due to the significant health risks associated with<space/><link><target>recreational drug use</target><part>recreational use</part></link>.#tag:ref</paragraph><paragraph>The first pharmaceutical amphetamine was<space/><link><target>Benzedrine</target></link>, a brand of inhalers used to treat a variety of conditions. Currently, pharmaceutical amphetamine is prescribed as racemic amphetamine,<space/><link><target>Adderall</target></link>,#tag:ref dextroamphetamine, or the inactive<space/><link><target>prodrug</target></link><space/><link><target>lisdexamfetamine</target></link>. Amphetamine, through activation of a<space/><link><target>TAAR1</target><part>trace amine receptor</part></link>, increases<space/><link><target>biogenic amine</target></link><space/>and<space/><link><target>Neurotransmitter#Excitatory and inhibitory</target><part>excitatory neurotransmitter</part></link><space/>activity in the brain, with its most pronounced effects targeting the<space/><link><target>catecholamine</target></link><space/>neurotransmitters<space/><link><target>norepinephrine</target></link><space/>and<space/><link><target>dopamine</target></link>. At therapeutic doses, this causes emotional and cognitive effects such as euphoria, change in<space/><link><target>libido</target></link>, increased<space/><link><target>wakefulness</target></link>, and improved<space/><link><target>cognitive control</target></link>. It induces physical effects such as decreased reaction time, fatigue resistance, and increased muscle strength.#tag:ref</paragraph><paragraph>Much larger doses of amphetamine may impair cognitive function and induce rapid muscle breakdown.<space/><link><target>Addiction</target><part>Drug addiction</part></link><space/>is a serious risk with large recreational doses, but rarely arises from medical use. Very high doses can result in<space/><link><target>Stimulant psychosis#Amphetamines</target><part>psychosis</part></link><space/>(e.g., delusions and paranoia) which rarely occurs at therapeutic doses even during long-term use. Recreational doses are generally much larger than prescribed therapeutic doses and carry a far greater risk of serious side effects.#tag:ref</paragraph><paragraph>Amphetamine belongs to the<space/><link><target>substituted phenethylamine</target><part>phenethylamine class</part></link>. It is also the parent compound of its own structural class, the<space/><link><target>substituted amphetamine</target><trail>s</trail></link>,#tag:ref which includes prominent substances such as<space/><link><target>bupropion</target></link>,<space/><link><target>cathinone</target></link>,<space/><link><target>MDMA</target></link><space/>(ecstasy), and<space/><link><target>methamphetamine</target></link>. As a member of the phenethylamine class, amphetamine is also chemically related to the naturally occurring<space/><link><target>trace amine</target></link><space/>neuromodulators, specifically<space/><link><target>phenethylamine</target></link>#tag:ref and<space/><template><target>nowrap</target><arg>[[N-methylphenethylamine|''N''-methylphenethylamine]]</arg></template>, both of which are produced within the human body. Phenethylamine is the parent compound of amphetamine, while<space/><template><target>nowrap</target><arg>''N''-methylphenethylamine</arg></template><space/>is a<space/><link><target>constitutional isomer</target></link><space/>that differs only in the placement of the methyl group.#tag:ref</paragraph><paragraph><template><target>TOC limit</target><arg>3</arg></template></paragraph><heading level='2'>Uses</heading><heading level='3'>Medical</heading><paragraph><extension extension_name='onlyinclude'><list type='numbered'><listitem>ifeq:</listitem></list></extension></paragraph><heading level='3'>Enhancing performance</heading><paragraph><extension extension_name='onlyinclude'><list type='numbered'><listitem>ifeq:</listitem></list></extension></paragraph><heading level='2'>Contraindications</heading><paragraph><template><target>see also</target><arg>Amphetamine#Interactions</arg></template><extension extension_name='onlyinclude'><list type='numbered'><listitem>ifeq:</listitem></list></extension></paragraph><heading level='2'>Side effects</heading><paragraph>The<space/><link><target>side effects</target></link><space/>of amphetamine are varied, and the amount of amphetamine used is the primary factor in determining the likelihood and severity of side effects.<extension extension_name='ref' name="FDA Abuse &amp; OD"></extension><extension extension_name='ref' name="FDA Effects"></extension><extension extension_name='ref' name="Westfall"></extension><space/>Amphetamine products such as<space/><link><target>Adderall</target></link>, Dexedrine, and their generic equivalents are currently approved by the USFDA for long-term therapeutic use.<extension extension_name='ref' name="NDCD"></extension><extension extension_name='ref' name="FDA Effects"></extension><space/><link><target>Recreational drug use#Stimulants</target><part>Recreational use</part></link><space/>of amphetamine generally involves much larger doses, which have a greater risk of serious side effects than dosages used for therapeutic reasons.<extension extension_name='ref' name="Westfall"></extension></paragraph><paragraph><extension extension_name='onlyinclude'><list type='numbered'><listitem>ifeq:</listitem></list></extension></paragraph><heading level='2'>Overdose</heading><paragraph><extension extension_name='onlyinclude'><list type='numbered'><listitem>ifeq:</listitem></list></extension></paragraph><heading level='2'>Interactions</heading><paragraph><template><target>see also</target><arg>Amphetamine#Contraindications</arg></template>Many types of substances are known to<space/><link><target>drug interaction</target><part>interact</part></link><space/>with amphetamine, resulting in altered<space/><link><target>drug action</target></link><space/>or<space/><link><target>Drug metabolism</target><part>metabolism</part></link><space/>of amphetamine, the interacting substance, or both.<extension extension_name='ref' name="FDA Pharmacokinetics"></extension><extension extension_name='ref' name="FDA Interactions"></extension><space/>Inhibitors of the enzymes that metabolize amphetamine (e.g., CYP2D6 and flavin-containing monooxygenase 3) will prolong its<space/><link><target>elimination half-life</target></link>, meaning that its effects will last longer.<extension extension_name='ref' name="FMO"></extension><extension extension_name='ref' name="FDA Interactions"><template><target>cite web</target><arg name="title"><space/>Adderall XR Prescribing Information<space/></arg><arg name="url"><space/>http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf<space/></arg><arg name="pages"><space/>8–10<space/></arg><arg name="publisher"><space/>Shire US Inc<space/></arg><arg name="work"><space/>United States Food and Drug Administration<space/></arg><arg name="date">December 2013<space/></arg><arg name="accessdate"><space/>30 December 2013<space/></arg></template></extension><space/>Amphetamine also interacts with<space/><template><target>abbr</target><arg>MAOIs</arg><arg>monoamine oxidase inhibitors</arg></template>, particularly<space/><link><target>monoamine oxidase A</target></link><space/>inhibitors, since both MAOIs and amphetamine increase plasma catecholamines (i.e., norepinephrine and dopamine);<extension extension_name='ref' name="FDA Interactions"></extension><space/>therefore, concurrent use of both is dangerous.<extension extension_name='ref' name="FDA Interactions"></extension><space/>Amphetamine modulates the activity of most psychoactive drugs. In particular, amphetamine may decrease the effects of<space/><link><target>sedative</target><trail>s</trail></link><space/>and<space/><link><target>depressant</target><trail>s</trail></link><space/>and increase the effects of<space/><link><target>stimulant</target><trail>s</trail></link><space/>and<space/><link><target>antidepressant</target><trail>s</trail></link>.<extension extension_name='ref' name="FDA Interactions"></extension><space/>Amphetamine may also decrease the effects of<space/><link><target>antihypertensives</target></link><space/>and<space/><link><target>antipsychotic</target><trail>s</trail></link><space/>due to its effects on blood pressure and dopamine respectively.<extension extension_name='ref' name="FDA Interactions"></extension><space/>In general, there is no significant interaction when consuming amphetamine with food, but the<space/><link><target>pH</target></link><space/>of gastrointestinal content and urine affects the absorption and excretion of amphetamine, respectively.<extension extension_name='ref' name="FDA Interactions"></extension><space/>Acidic substances reduce the absorption of amphetamine and increase urinary excretion, and alkaline substances do the opposite.<extension extension_name='ref' name="FDA Interactions"></extension><space/>Due to the effect pH has on absorption, amphetamine also interacts with gastric acid reducers such as<space/><link><target>proton pump inhibitor</target><trail>s</trail></link><space/>and<space/><link><target>H2 antagonist</target><part>H<xhtml:sub>2</xhtml:sub><space/>antihistamines</part></link>, which increase gastrointestinal pH (i.e., make it less acidic).<extension extension_name='ref' name="FDA Interactions"></extension></paragraph><heading level='2'>Pharmacology</heading><heading level='3'>Pharmacodynamics</heading><paragraph><template><target>For</target><arg>a simpler and less technical explanation of amphetamine's mechanism of action</arg><arg>Adderall#Mechanism of action</arg></template><template><target>amphetamine pharmacodynamics</target></template>Amphetamine exerts its behavioral effects by altering the use of<space/><link><target>monoamines</target></link><space/>as neuronal signals in the brain, primarily in<space/><link><target>catecholamine</target></link><space/>neurons in the reward and executive function pathways of the brain.<extension extension_name='ref' name="Miller"></extension><extension extension_name='ref' name="cognition enhancers"></extension><space/>The concentrations of the main neurotransmitters involved in reward circuitry and executive functioning, dopamine and norepinephrine, increase dramatically in a dose-dependent manner by amphetamine due to its effects on monoamine transporters.<extension extension_name='ref' name="Miller"></extension><extension extension_name='ref' name="cognition enhancers"></extension><extension extension_name='ref' name="E Weihe"></extension><space/>The reinforcing and task<space/><link><target>Salience (neuroscience)</target><part>saliency</part></link><space/>effects of amphetamine are mostly due to enhanced dopaminergic activity in the<space/><link><target>mesolimbic pathway</target></link>.<extension extension_name='ref' name="Malenka_2009"></extension></paragraph><paragraph>Amphetamine has been identified as a potent<space/><link><target>full agonist</target></link><space/>of<space/><link><target>TAAR1</target><part>trace amine-associated receptor 1</part></link><space/>(TAAR1), a<space/><template><target>nowrap</target><arg>[[Gs alpha subunit|G<sub>s</sub>-coupled]]</arg></template><space/>and<space/><template><target>nowrap</target><arg>[[Gq alpha subunit|G<sub>q</sub>-coupled]]</arg></template><space/><link><target>G protein-coupled receptor</target></link><space/>(GPCR) discovered in 2001, which is important for regulation of brain monoamines.<extension extension_name='ref' name="Miller"></extension><extension extension_name='ref' name="TAAR1 IUPHAR"><template><target>cite web</target><arg name="title">TA<sub>1</sub><space/>receptor</arg><arg name="url">http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId</arg><arg name="work">IUPHAR database</arg><arg name="publisher">International Union of Basic and Clinical Pharmacology</arg><arg name="accessdate">8 December 2014</arg><arg name="author">Maguire JJ, Davenport AP</arg><arg name="date">2 December 2014</arg><arg name="quote"></arg></template></extension><space/>Activation of<space/><template><target>abbr</target><arg>TAAR1</arg><arg>trace amine-associated receptor 1</arg></template><space/>increases<space/><template><target>abbrlink</target><arg>cAMP</arg><arg>cyclic adenosine monophosphate</arg></template><space/>production via<space/><link><target>adenylyl cyclase</target></link><space/>activation and inhibits<space/><link><target>monoamine transporter</target></link><space/>function.<extension extension_name='ref' name="Miller"></extension><extension extension_name='ref' name="pmid11459929"><template><target>cite journal</target><arg name="author"><space/>Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C<space/></arg><arg name="title"><space/>Trace amines: identification of a family of mammalian G protein-coupled receptors<space/></arg><arg name="journal"><space/>Proc. Natl. Acad. Sci. U.S.A.<space/></arg><arg name="volume"><space/>98<space/></arg><arg name="issue"><space/>16<space/></arg><arg name="pages"><space/>8966–8971<space/></arg><arg name="date">July 2001<space/></arg><arg name="pmid"><space/>11459929<space/></arg><arg name="pmc"><space/>55357<space/></arg><arg name="doi"><space/>10.1073/pnas.151105198</arg></template></extension><space/>Monoamine<space/><link><target>autoreceptors</target></link><space/>(e.g.,<space/><link><target>D2sh</target><part>D<xhtml:sub>2</xhtml:sub><space/>short</part></link>,<space/><link><target>Alpha-2 adrenergic receptor</target><part>presynaptic<space/><xhtml:sub>2</xhtml:sub></part></link>, and<space/><link><target>5-HT1A#Autoreceptors</target><part>presynaptic 5-HT<xhtml:sub>1A</xhtml:sub></part></link>) have the opposite effect of TAAR1, and together these receptors provide a regulatory system for monoamines.<extension extension_name='ref' name="Miller"></extension><space/>Notably, amphetamine and<space/><link><target>trace amine</target><trail>s</trail></link><space/>bind to TAAR1, but not monoamine autoreceptors.<extension extension_name='ref' name="Miller"></extension><space/>Imaging studies indicate that monoamine reuptake inhibition by amphetamine and trace amines is site specific and depends upon the presence of TAAR1<space/><template><target>nowrap</target><arg>co-localization</arg></template><space/>in the associated monoamine neurons.<extension extension_name='ref' name="Miller"></extension><space/><template><target>As of</target><arg>2014</arg><arg name="alt">As of 2010,</arg></template><space/><template><target>nowrap</target><arg>co-localization</arg></template><space/>of TAAR1 and the<space/><link><target>dopamine transporter</target></link><space/>(DAT) has been visualized in rhesus monkeys, but<space/><template><target>nowrap</target><arg>co-localization</arg></template><space/>of TAAR1 with the<space/><link><target>norepinephrine transporter</target></link><space/>(NET) and the<space/><link><target>serotonin transporter</target></link><space/>(SERT) has only been evidenced by<space/><link><target>messenger RNA</target></link><space/>(mRNA) expression.<extension extension_name='ref' name="Miller"></extension></paragraph><paragraph>In addition to the neuronal monoamine<space/><link><target>Membrane transport protein</target><part>transporters</part></link>, amphetamine also inhibits<space/><link><target>vesicular monoamine transporter 2</target></link><space/>(VMAT2),<space/><link><target>SLC1A1</target></link>,<space/><link><target>SLC22A3</target></link>, and<space/><link><target>SLC22A5</target></link>.#tag:ref SLC1A1 is<space/><link><target>excitatory amino acid transporter 3</target></link><space/>(EAAT3), a glutamate transporter located in neurons, SLC22A3 is an extraneuronal monoamine transporter that is present in<space/><link><target>astrocyte</target><trail>s</trail></link><space/>and SLC22A5 is a high-affinity<space/><link><target>carnitine</target></link><space/>transporter.<extension extension_name='ref' name="Reuptake inhibition" group="sources"></extension><space/>Amphetamine is known to strongly induce<space/><link><target>cocaine- and amphetamine-regulated transcript</target></link><space/>(CART)<space/><link><target>gene expression</target></link>,<extension extension_name='ref' name="CART NAcc"><template><target>cite journal</target><arg name="author"><space/>Vicentic A, Jones DC<space/></arg><arg name="title"><space/>The CART (cocaine- and amphetamine-regulated transcript) system in appetite and drug addiction<space/></arg><arg name="journal"><space/>J. Pharmacol. Exp. Ther.<space/></arg><arg name="volume"><space/>320<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>499–506<space/></arg><arg name="date">February 2007<space/></arg><arg name="pmid"><space/>16840648<space/></arg><arg name="doi"><space/>10.1124/jpet.105.091512<space/></arg><arg name="quote"><space/>The physiological importance of CART was further substantiated in numerous human studies demonstrating a role of CART in both feeding and psychostimulant addiction.&nbsp;... Colocalization studies also support a role for CART in the actions of psychostimulants.&nbsp;... CART and {{abbr|DA|dopamine}} receptor transcripts colocalize (Beaudry et al., 2004). Second, dopaminergic nerve terminals in the {{abbr|NAc|nucleus accumbens}} synapse on CART-containing neurons (Koylu et al., 1999), hence providing the proximity required for neurotransmitter signaling. These studies suggest that DA plays a role in regulating CART gene expression possibly via the activation of {{abbr|CREB|cAMP response element-binding protein}}.</arg></template></extension><extension extension_name='ref' name="PubChem Targets"></extension><space/>a<space/><link><target>neuropeptide</target></link><space/>involved in feeding behavior, stress, and reward, which induces observable increases in neuronal development and survival<space/><italics><link><target>in vitro</target></link></italics>.<extension extension_name='ref' name="PubChem Targets"><template><target>cite encyclopedia</target><arg name="title">Amphetamine<space/></arg><arg name="section-url">http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid</arg><arg name="work">PubChem Compound<space/></arg><arg name="publisher"><space/>National Center for Biotechnology Information<space/></arg><arg name="accessdate">13 October 2013<space/></arg><arg name="section">Biomolecular Interactions and Pathways<space/></arg></template></extension><extension extension_name='ref' name="CART functions"><template><target>cite journal</target><arg name="author"><space/>Zhang M, Han L, Xu Y<space/></arg><arg name="title"><space/>Roles of cocaine- and amphetamine-regulated transcript in the central nervous system<space/></arg><arg name="journal"><space/>Clin. Exp. Pharmacol. Physiol.<space/></arg><arg name="volume"><space/>39<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>586–592<space/></arg><arg name="date">June 2012<space/></arg><arg name="pmid"><space/>22077697<space/></arg><arg name="doi"><space/>10.1111/j.1440-1681.2011.05642.x<space/></arg><arg name="quote"><space/>Recently, it was demonstrated that CART, as a neurotrophic peptide, had a cerebroprotective against focal ischaemic stroke and inhibited the neurotoxicity of β-amyloid protein, which focused attention on the role of CART in the central nervous system (CNS) and neurological diseases. 3. In fact, little is known about the way in which CART peptide interacts with its receptors, initiates downstream cascades and finally exerts its neuroprotective effect under normal or pathological conditions. The literature indicates that there are many factors, such as regulation of the immunological system and protection against energy failure, that may be involved in the cerebroprotection afforded by CART</arg></template></extension><extension extension_name='ref' name="CART"><template><target>cite journal</target><arg name="vauthors"><space/>Rogge G, Jones D, Hubert GW, Lin Y, Kuhar MJ<space/></arg><arg name="title"><space/>CART peptides: regulators of body weight, reward and other functions<space/></arg><arg name="journal"><space/>Nat. Rev. Neurosci.<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>747–758<space/></arg><arg name="date"><space/>October 2008<space/></arg><arg name="pmid"><space/>18802445<space/></arg><arg name="pmc"><space/>4418456<space/></arg><arg name="doi"><space/>10.1038/nrn2493<space/></arg><arg name="quote"><space/>Several studies on CART (cocaine- and amphetamine-regulated transcript)-peptide-induced cell signalling have demonstrated that CART peptides activate at least three signalling mechanisms. First, CART 55–102 inhibited voltage-gated L-type Ca2+ channels&nbsp;...</arg></template></extension><space/>The CART receptor has yet to be identified, but there is significant evidence that CART binds to a unique<space/><template><target>nowrap</target><arg>[[Gi alpha subunit|G<sub>i</sub>/G<sub>o</sub>-coupled]]</arg></template><space/><template><target>abbr</target><arg>GPCR</arg><arg>G protein-coupled receptor</arg></template>.<extension extension_name='ref' name="CART"></extension><extension extension_name='ref' name="pmid21855138"><template><target>cite journal</target><arg name="author"><space/>Lin Y, Hall RA, Kuhar MJ<space/></arg><arg name="title"><space/>CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: identification of PACAP 6–38 as a CART receptor antagonist<space/></arg><arg name="journal"><space/>Neuropeptides<space/></arg><arg name="volume"><space/>45<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>351–358<space/></arg><arg name="date">October 2011<space/></arg><arg name="pmid"><space/>21855138<space/></arg><arg name="pmc"><space/>3170513<space/></arg><arg name="doi"><space/>10.1016/j.npep.2011.07.006<space/></arg></template></extension><space/>Amphetamine also inhibits<space/><link><target>monoamine oxidase</target></link><space/>at very high doses, resulting in less dopamine and phenethylamine metabolism and consequently higher concentrations of synaptic monoamines.<extension extension_name='ref' name="PubChem Header"><template><target>cite encyclopedia</target><arg name="title">Amphetamine<space/></arg><arg name="section-url">http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid</arg><arg name="work">PubChem Compound<space/></arg><arg name="publisher"><space/>National Center for Biotechnology Information<space/></arg><arg name="accessdate">17 April 2015<space/></arg><arg name="date">11 April 2015<space/></arg><arg name="section">Compound Summary<space/></arg></template></extension><extension extension_name='ref' name="BRENDA MAO Homo sapiens"><template><target>cite encyclopedia</target><arg name="title">Monoamine oxidase (Homo sapiens)</arg><arg name="url">http://www.brenda-enzymes.info/enzyme.php?ecno</arg><arg name="work">BRENDA<space/></arg><arg name="publisher">Technische Universität Braunschweig<space/></arg><arg name="accessdate">4 May 2014<space/></arg><arg name="date">1 January 2014</arg></template></extension><space/>In humans, the only post-synaptic receptor at which amphetamine is known to bind is the<space/><link><target>5-HT1A receptor</target><part><template><target>nowrap</target><arg>5-HT1A</arg></template><space/>receptor</part></link>, where it acts as an agonist with<space/><link><target>micromolar</target></link><space/>affinity.<extension extension_name='ref' name="5HT1A secondary"></extension><extension extension_name='ref' name="5HT1A Primary"></extension></paragraph><paragraph>The full profile of amphetamine's short-term drug effects is mostly derived through increased cellular communication or<space/><link><target>neurotransmission</target></link><space/>of<space/><link><target>dopamine</target></link>,<extension extension_name='ref' name="Miller"><template><target>cite journal</target><arg name="author"><space/>Miller GM<space/></arg><arg name="title"><space/>The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity<space/></arg><arg name="journal"><space/>J. Neurochem.<space/></arg><arg name="volume"><space/>116<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>164–176<space/></arg><arg name="date">January 2011<space/></arg><arg name="pmid"><space/>21073468<space/></arg><arg name="pmc"><space/>3005101<space/></arg><arg name="doi"><space/>10.1111/j.1471-4159.2010.07109.x<space/></arg></template></extension><space/><link><target>serotonin</target></link>,<extension extension_name='ref' name="Miller"></extension><space/><link><target>norepinephrine</target></link>,<extension extension_name='ref' name="Miller"></extension><space/><link><target>epinephrine</target></link>,<extension extension_name='ref' name="E Weihe"><template><target>cite journal</target><arg name="author"><space/>Eiden LE, Weihe E<space/></arg><arg name="title"><space/>VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse<space/></arg><arg name="journal"><space/>Ann. N. Y. Acad. Sci.<space/></arg><arg name="volume"><space/>1216<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>86–98<space/></arg><arg name="date">January 2011<space/></arg><arg name="pmid"><space/>21272013<space/></arg><arg name="doi"><space/>10.1111/j.1749-6632.2010.05906.x<space/></arg><arg name="quote"></arg></template></extension><space/><link><target>histamine</target></link>,<extension extension_name='ref' name="E Weihe"></extension><space/><link><target>cocaine and amphetamine regulated transcript</target><part>CART peptides</part></link>,<extension extension_name='ref' name="CART NAcc"></extension><extension extension_name='ref' name="PubChem Targets"></extension><space/><link><target>acetylcholine</target></link>,<extension extension_name='ref' name="Acetylcholine"><template><target>cite journal</target><arg name="author"><space/>Hutson PH, Tarazi FI, Madhoo M, Slawecki C, Patkar AA<space/></arg><arg name="title"><space/>Preclinical pharmacology of amphetamine: implications for the treatment of neuropsychiatric disorders<space/></arg><arg name="journal"><space/>Pharmacol. Ther.<space/></arg><arg name="volume"><space/>143<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>253–264<space/></arg><arg name="date"><space/>September 2014<space/></arg><arg name="pmid"><space/>24657455<space/></arg><arg name="doi"><space/>10.1016/j.pharmthera.2014.03.005<space/></arg><arg name="url"><space/></arg></template></extension><extension extension_name='ref' name="MEDRS-Cholinergic"><template><target>cite journal</target><arg name="author"><space/>Dickson SL, Egecioglu E, Landgren S, Skibicka KP, Engel JA, Jerlhag E<space/></arg><arg name="title"><space/>The role of the central ghrelin system in reward from food and chemical drugs<space/></arg><arg name="journal"><space/>Mol. Cell. Endocrinol.<space/></arg><arg name="volume"><space/>340<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>80–87<space/></arg><arg name="date">June 2011<space/></arg><arg name="pmid"><space/>21354264<space/></arg><arg name="doi"><space/>10.1016/j.mce.2011.02.017<space/></arg></template></extension><space/><link><target>endogenous opioid</target><trail>s</trail></link>,<extension extension_name='ref' name="Opioids"><template><target>cite journal</target><arg name="vauthors"><space/>Loseth GE, Ellingsen DM, Leknes S<space/></arg><arg name="title"><space/>State-dependent μ-opioid modulation of social motivation<space/></arg><arg name="journal"><space/>Front. Behav. Neurosci.<space/></arg><arg name="volume"><space/>8<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>1–15<space/></arg><arg name="date"><space/>December 2014<space/></arg><arg name="pmid"><space/>25565999<space/></arg><arg name="pmc"><space/>4264475<space/></arg><arg name="doi"><space/>10.3389/fnbeh.2014.00430<space/></arg><arg name="quote"><space/>Similar MOR activation patterns were reported during positive mood induced by an amusing video clip (Koepp et al., 2009) and following amphetamine administration in humans (Colasanti et al., 2012).<space/></arg></template></extension><extension extension_name='ref' name="Opioids cited primary source"><template><target>cite journal</target><arg name="vauthors"><space/>Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D, Erritzoe D, Tziortzi AC, Reed LJ, Lingford-Hughes AR, Waldman AD, Schruers KR, Matthews PM, Gunn RN, Nutt DJ, Rabiner EA<space/></arg><arg name="title"><space/>Endogenous opioid release in the human brain reward system induced by acute amphetamine administration<space/></arg><arg name="journal"><space/>Biol. Psychiatry<space/></arg><arg name="volume"><space/>72<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>371–377<space/></arg><arg name="date"><space/>September 2012<space/></arg><arg name="pmid"><space/>22386378<space/></arg><arg name="doi"><space/>10.1016/j.biopsych.2012.01.027<space/></arg><arg name="quote"><space/></arg></template></extension><space/>and<space/><link><target>glutamate</target></link>,<extension extension_name='ref' name="Glutamate-dopamine cotransmission review"></extension><extension extension_name='ref' name="glutamate1"><template><target>cite journal</target><arg name="author"><space/>Stuber GD, Hnasko TS, Britt JP, Edwards RH, Bonci A<space/></arg><arg name="title"><space/>Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate<space/></arg><arg name="journal"><space/>J. Neurosci.<space/></arg><arg name="volume"><space/>30<space/></arg><arg name="issue"><space/>24<space/></arg><arg name="pages"><space/>8229–8233<space/></arg><arg name="date">June 2010<space/></arg><arg name="pmid"><space/>20554874<space/></arg><arg name="pmc"><space/>2918390<space/></arg><arg name="doi"><space/>10.1523/JNEUROSCI.1754-10.2010<space/></arg></template></extension><space/>which it effects through interactions with<space/><template><target>abbr</target><arg>CART</arg><arg>cocaine- and amphetamine-regulated transcript</arg></template>,<space/><template><target>nowrap</target><arg>{{abbr|5-HT1A|serotonin receptor 1A}}</arg></template>,<space/><template><target>abbr</target><arg>EAAT3</arg><arg>excitatory amino acid transporter 3</arg></template>,<space/><template><target>abbr</target><arg>TAAR1</arg><arg>trace amine-associated receptor 1</arg></template>, and<space/><template><target>abbr</target><arg>VMAT2</arg><arg>vesicular monoamine transporter 2</arg></template>.#tag:ref</paragraph><paragraph>Dextroamphetamine is a more potent agonist of<space/><template><target>abbr</target><arg>TAAR1</arg><arg>trace amine-associated receptor 1</arg></template><space/>than levoamphetamine.<extension extension_name='ref' name="TAAR1 stereoselective"></extension><space/>Consequently, dextroamphetamine produces greater<space/><template><target>abbr</target><arg>CNS</arg><arg>central nervous system</arg></template><space/>stimulation than levoamphetamine, roughly three to four times more, but levoamphetamine has slightly stronger cardiovascular and peripheral effects.<extension extension_name='ref' name="Westfall"></extension><extension extension_name='ref' name="TAAR1 stereoselective"><template><target>cite journal</target><arg name="author"><space/>Lewin AH, Miller GM, Gilmour B<space/></arg><arg name="title">Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class<space/></arg><arg name="journal">Bioorg. Med. Chem.<space/></arg><arg name="date">December 2011<space/></arg><arg name="volume">19<space/></arg><arg name="issue">23<space/></arg><arg name="pages">7044–7048<space/></arg><arg name="pmid">22037049<space/></arg><arg name="doi"><space/>10.1016/j.bmc.2011.10.007<space/></arg><arg name="pmc"><space/>3236098</arg></template></extension></paragraph><heading level='4'>Dopamine</heading><paragraph>In certain brain regions, amphetamine increases the concentration of dopamine in the<space/><link><target>synaptic cleft</target></link>.<extension extension_name='ref' name="Miller"></extension><space/>Amphetamine can enter the<space/><link><target>presynaptic neuron</target></link><space/>either through<space/><template><target>abbr</target><arg>DAT</arg><arg>dopamine transporter</arg></template><space/>or by diffusing across the neuronal membrane directly.<extension extension_name='ref' name="Miller"></extension><space/>As a consequence of DAT uptake, amphetamine produces competitive reuptake inhibition at the transporter.<extension extension_name='ref' name="Miller"></extension><space/>Upon entering the presynaptic neuron, amphetamine activates<space/><template><target>abbr</target><arg>TAAR1</arg><arg>trace amine-associated receptor 1</arg></template><space/>which, through<space/><link><target>protein kinase A</target></link><space/>(PKA) and<space/><link><target>protein kinase C</target></link><space/>(PKC) signaling, causes DAT<space/><link><target>phosphorylation</target></link>.<extension extension_name='ref' name="Miller"></extension><space/>Phosphorylation by either protein kinase can result in DAT<space/><link><target>endocytosis</target><part>internalization</part></link><space/>(<template><target>nowrap</target><arg>non-competitive</arg></template><space/>reuptake inhibition), but<space/><template><target>nowrap</target><arg>PKC-mediated</arg></template><space/>phosphorylation alone induces reverse transporter function (dopamine<space/><link><target>wikt:efflux</target><part>efflux</part></link>).<extension extension_name='ref' name="Miller"></extension><extension extension_name='ref' name="TAAR1 Review"><template><target>cite journal</target><arg name="author"><space/>Maguire JJ, Parker WA, Foord SM, Bonner TI, Neubig RR, Davenport AP<space/></arg><arg name="title"><space/>International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature<space/></arg><arg name="journal"><space/>Pharmacol. Rev.<space/></arg><arg name="volume"><space/>61<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>1–8<space/></arg><arg name="date">March 2009<space/></arg><arg name="pmid"><space/>19325074<space/></arg><arg name="pmc"><space/>2830119<space/></arg><arg name="doi"><space/>10.1124/pr.109.001107<space/></arg></template></extension><space/>Amphetamine is also known to increase intracellular calcium, a known effect of TAAR1 activation, which is associated with DAT phosphorylation through a<space/><link><target>Ca2+/calmodulin-dependent protein kinase</target></link><space/>(CAMK)-dependent pathway, in turn producing dopamine efflux.<extension extension_name='ref' name="TAAR1 IUPHAR"></extension><extension extension_name='ref' name="EAAT3"></extension><extension extension_name='ref' name="DAT regulation review"><template><target>cite journal</target><arg name="author"><space/>Vaughan RA, Foster JD<space/></arg><arg name="title"><space/>Mechanisms of dopamine transporter regulation in normal and disease states<space/></arg><arg name="journal"><space/>Trends Pharmacol. Sci.<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>489–496<space/></arg><arg name="date"><space/>September 2013<space/></arg><arg name="pmid"><space/>23968642<space/></arg><arg name="pmc"><space/>3831354<space/></arg><arg name="doi"><space/>10.1016/j.tips.2013.07.005<space/></arg><arg name="quote"><space/></arg></template></extension><space/>Through direct activation of<space/><link><target>G protein-coupled inwardly-rectifying potassium channel</target><trail>s</trail></link><space/>and an indirect increase in dopamine autoreceptor signaling,<space/><template><target>abbr</target><arg>TAAR1</arg><arg>trace amine associated receptor 1</arg></template><space/>reduces the<space/><link><target>action potential</target><part>firing rate</part></link><space/>of postsynaptic dopamine receptors, preventing a hyper-dopaminergic state.<extension extension_name='ref' name="GIRK"><template><target>cite journal</target><arg name="author"><space/>Ledonne A, Berretta N, Davoli A, Rizzo GR, Bernardi G, Mercuri NB<space/></arg><arg name="title"><space/>Electrophysiological effects of trace amines on mesencephalic dopaminergic neurons<space/></arg><arg name="journal"><space/>Front. Syst. Neurosci.<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>56<space/></arg><arg name="date"><space/>July 2011<space/></arg><arg name="pmid"><space/>21772817<space/></arg><arg name="pmc"><space/>3131148<space/></arg><arg name="doi"><space/>10.3389/fnsys.2011.00056<space/></arg><arg name="quote"><space/></arg></template></extension><extension extension_name='ref' name="Genatlas TAAR1"><template><target>cite web</target><arg name="url"><space/>http://genatlas.medecine.univ-paris5.fr/fiche.php?symbol</arg><arg name="title"><space/>TAAR1<space/></arg><arg name="author"><space/>mct<space/></arg><arg name="date"><space/>28 January 2012<space/></arg><arg name="work"><space/>GenAtlas<space/></arg><arg name="publisher"><space/>University of Paris<space/></arg><arg name="accessdate"><space/>29 May 2014<space/></arg><arg name="quote"><br />{{bull}} tonically activates inwardly rectifying K(+) channels, which reduces the basal firing frequency of dopamine (DA) neurons of the ventral tegmental area (VTA)<space/></arg></template></extension><extension extension_name='ref' name="TAAR1-Paradoxical"><template><target>cite journal</target><arg name="author">Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, Durkin S, Zbinden KG, Norcross R, Meyer CA, Metzler V, Chaboz S, Ozmen L, Trube G, Pouzet B, Bettler B, Caron MG, Wettstein JG, Hoener MC<space/></arg><arg name="title">TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity<space/></arg><arg name="journal">Proc. Natl. Acad. Sci. U.S.A.<space/></arg><arg name="volume">108<space/></arg><arg name="issue">20<space/></arg><arg name="pages">8485–8490<space/></arg><arg name="date">May 2011<space/></arg><arg name="pmid">21525407<space/></arg><arg name="pmc">3101002<space/></arg><arg name="doi">10.1073/pnas.1103029108</arg></template></extension></paragraph><paragraph>Amphetamine is also a substrate for the presynaptic vesicular monoamine transporter,<space/><template><target>abbr</target><arg>VMAT2</arg><arg>vesicular monoamine transporter 2</arg></template>.<extension extension_name='ref' name="E Weihe"></extension><space/>Following amphetamine uptake at VMAT2, the<space/><link><target>synaptic vesicle</target></link><space/>releases dopamine molecules into the<space/><link><target>cytosol</target></link><space/>in exchange.<extension extension_name='ref' name="E Weihe"></extension><space/>Subsequently, the cytosolic dopamine molecules exit the presynaptic neuron via reverse transport at<space/><template><target>abbr</target><arg>DAT</arg><arg>dopamine transporter</arg></template>.<extension extension_name='ref' name="Miller"></extension><extension extension_name='ref' name="E Weihe"></extension></paragraph><heading level='4'>Norepinephrine</heading><paragraph>Similar to dopamine, amphetamine dose-dependently increases the level of synaptic norepinephrine, the direct precursor of<space/><link><target>epinephrine</target></link>.<extension extension_name='ref' name="Trace Amines"></extension><extension extension_name='ref' name="cognition enhancers"></extension><space/>Based upon neuronal<space/><template><target>abbr</target><arg>TAAR1</arg><arg>trace amine-associated receptor 1</arg></template><space/><template><target>abbr</target><arg>mRNA</arg><arg>messenger RNA</arg></template><space/>expression, amphetamine is thought to affect norepinephrine analogously to dopamine.<extension extension_name='ref' name="Miller"></extension><extension extension_name='ref' name="E Weihe"></extension><extension extension_name='ref' name="TAAR1 Review"></extension><space/>In other words, amphetamine induces TAAR1-mediated efflux and<space/><template><target>nowrap</target><arg>non-competitive</arg></template><space/>reuptake inhibition at phosphorylated<space/><template><target>abbr</target><arg>NET</arg><arg>norepinephrine transporter</arg></template>, competitive NET reuptake inhibition, and norepinephrine release from<space/><template><target>abbr</target><arg>VMAT2</arg><arg>vesicular monoamine transporter 2</arg></template>.<extension extension_name='ref' name="Miller"></extension><extension extension_name='ref' name="E Weihe"></extension></paragraph><heading level='4'>Serotonin</heading><paragraph>Amphetamine exerts analogous, yet less pronounced, effects on serotonin as on dopamine and norepinephrine.<extension extension_name='ref' name="Miller"></extension><extension extension_name='ref' name="cognition enhancers"></extension><space/>Amphetamine affects serotonin via<space/><template><target>abbr</target><arg>VMAT2</arg><arg>vesicular monoamine transporter 2</arg></template><space/>and, like norepinephrine, is thought to phosphorylate<space/><template><target>abbr</target><arg>SERT</arg><arg>serotonin transporter</arg></template><space/>via<space/><template><target>abbr</target><arg>TAAR1</arg><arg>trace amine-associated receptor 1</arg></template>.<extension extension_name='ref' name="Miller"></extension><extension extension_name='ref' name="E Weihe"></extension><space/>Like dopamine, amphetamine has low, micromolar affinity at the human<space/><link><target>5-HT1A receptor</target></link>.<extension extension_name='ref' name="5HT1A secondary"><template><target>cite encyclopedia</target><arg name="title">Amphetamine<space/></arg><arg name="url">http://www.t3db.ca/toxins/T3D2706<space/></arg><arg name="website">T3DB<space/></arg><arg name="publisher">University of Alberta<space/></arg><arg name="accessdate">24 February 2015<space/></arg><arg name="section">Targets</arg></template></extension><extension extension_name='ref' name="5HT1A Primary"><template><target>cite journal</target><arg name="vauthors"><space/>Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS<space/></arg><arg name="title"><space/>Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications<space/></arg><arg name="journal"><space/>NIDA Res. Monogr.<space/></arg><arg name="volume"><space/>178<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>440–466<space/></arg><arg name="date"><space/>March 1998<space/></arg><arg name="pmid"><space/>9686407<space/></arg><arg name="doi"><space/></arg><arg name="url"><space/></arg></template></extension><space/></paragraph><heading level='4'>Other neurotransmitters and peptides</heading><paragraph>Amphetamine has no direct effect on<space/><link><target>acetylcholine</target></link><space/>neurotransmission, but several studies have noted that acetylcholine release increases after its use.<extension extension_name='ref' name="Acetylcholine"></extension><extension extension_name='ref' name="MEDRS-Cholinergic"></extension><space/>In lab animals, amphetamine increases acetylcholine levels in certain brain regions as a downstream effect.<extension extension_name='ref' name="Acetylcholine"></extension><space/>In humans, a similar phenomenon occurs via the<space/><link><target>ghrelin</target></link>-mediated<space/><link><target>cholinergicdopaminergic reward link</target></link><space/>in the<space/><link><target>ventral tegmental area</target></link>.<extension extension_name='ref' name="MEDRS-Cholinergic"></extension><space/>Acute amphetamine administration in humans also increases<space/><link><target>endogenous opioid</target></link><space/>release in several brain structures in the<space/><link><target>reward system</target></link>.<extension extension_name='ref' name="Opioids"></extension><extension extension_name='ref' name="Opioids cited primary source"></extension></paragraph><paragraph>Extracellular levels of<space/><link><target>glutamate</target></link>, the primary<space/><link><target>Neurotransmitter#Excitatory and inhibitory</target><part>excitatory neurotransmitter</part></link><space/>in the brain, have been shown to increase upon exposure to amphetamine.<extension extension_name='ref' name="Glutamate-dopamine cotransmission review"></extension><extension extension_name='ref' name="glutamate1"></extension><space/>This<space/><link><target>cotransmission</target></link><space/>effect was found in the mesolimbic pathway, an area of the brain implicated in reward, where amphetamine is known to affect dopamine neurotransmission.<extension extension_name='ref' name="Glutamate-dopamine cotransmission review"></extension><extension extension_name='ref' name="glutamate1"></extension><space/>Amphetamine also induces the selective release of<space/><link><target>histamine</target></link><space/>from vesicles in<space/><template><target>abbr</target><arg>CNS</arg><arg>central nervous system</arg></template><space/><link><target>mast cell</target><trail>s</trail></link><space/>and efflux from histaminergic neurons through<space/><template><target>abbr</target><arg>VMAT2</arg><arg>vesicular monoamine transporter 2</arg></template>.<extension extension_name='ref' name="E Weihe"></extension></paragraph><heading level='3'>Pharmacokinetics</heading><paragraph><extension extension_name='onlyinclude'><list type='numbered'><listitem>ifeq:</listitem></list></extension></paragraph><heading level='3'>Related endogenous compounds</heading><paragraph><extension extension_name='onlyinclude'><list type='numbered'><listitem>ifeq:</listitem></list></extension></paragraph><heading level='2'>Physical and chemical properties</heading><paragraph><template><target>Annotated image 4</target><arg name="caption"><space/>The [[skeletal structure]]s of {{abbr|L-amph|Levoamphetamine}} and {{abbr|D-amph|Dextroamphetamine}}
</arg><arg name="header"><space/>Racemic amphetamine
</arg><arg name="header_align"><space/>center
</arg><arg name="header_background"><space/>aliceblue
</arg><arg name="alt"><space/>Graphical representation of Amphetamine stereoisomers
</arg><arg name="image"><space/>Racemic_amphetamine.svg
</arg><arg name="align"><space/>right
</arg><arg name="image-width"><space/>300
</arg><arg name="image-left"><space/>0
</arg><arg name="image-top"><space/>0
</arg><arg name="width"><space/>300
</arg><arg name="height"><space/>76
</arg><arg name="annot-font-size"><space/>14
</arg><arg name="annot-text-align"><space/>left
</arg><arg name="annotations">
{{Annotation|5|60|[[Levoamphetamine]]}}
{{Annotation|170|60|[[Dextroamphetamine]]}}
</arg></template><template><target>multiple image</target><arg name="align"><space/>right
</arg><arg name="direction"><space/>vertical
</arg><arg name="width"><space/>300
<space/></arg><arg name="image1">Amphetamine Freebase.png
</arg><arg name="caption1">A vial of the colorless amphetamine free base
</arg><arg name="alt1">An image of amphetamine free base
</arg><arg name="image2">Amphetamine and P2P.png
</arg><arg name="caption2">Amphetamine hydrochloride (left bowl)<br />[[Phenyl-2-nitropropene]] (right cups)
</arg><arg name="alt2">An image of phenyl-2-nitropropene and amphetamine hydrochloride
</arg></template></paragraph><paragraph>Amphetamine is a<space/><link><target>methyl</target></link><space/><link><target>homologous series</target><part>homolog</part></link><space/>of the mammalian neurotransmitter phenethylamine with the chemical formula<space/><template><target>chemical formula</target><arg>C</arg><arg>9</arg><arg>H</arg><arg>13</arg><arg>N</arg></template>. The carbon atom adjacent to the<space/><link><target>primary amine</target></link><space/>is a<space/><link><target>stereogenic center</target></link>, and amphetamine is composed of a<space/><link><target>racemic</target></link><space/>1:1 mixture of two<space/><link><target>enantiomer</target><trail>ic</trail></link><space/>mirror images.<extension extension_name='ref' name="DrugBank1"><template><target>cite encyclopedia</target><arg name="title">Amphetamine<space/></arg><arg name="section-url">http://www.drugbank.ca/drugs/DB00182#identification<space/></arg><arg name="section">Identification<space/></arg><arg name="work">DrugBank<space/></arg><arg name="publisher"><space/>University of Alberta<space/></arg><arg name="accessdate">13 October 2013<space/></arg><arg name="date">8 February 2013<space/></arg></template></extension><space/>This racemic mixture can be separated into its optical isomers:#tag:ref<space/><link><target>levoamphetamine</target></link><space/>and<space/><link><target>dextroamphetamine</target></link>.<extension extension_name='ref' name="DrugBank1"></extension><space/>Physically, at room temperature, the pure free base of amphetamine is a mobile, colorless, and<space/><link><target>Volatility (chemistry)</target><part>volatile</part></link><space/><link><target>liquid</target></link><space/>with a characteristically strong<space/><link><target>amine</target></link><space/>odor, and acrid, burning taste.<extension extension_name='ref' name="Properties"><template><target>cite encyclopedia</target><arg name="title">Amphetamine<space/></arg><arg name="section-url">http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid</arg><arg name="work">PubChem Compound<space/></arg><arg name="publisher"><space/>National Center for Biotechnology Information<space/></arg><arg name="accessdate">13 October 2013<space/></arg><arg name="section">Chemical and Physical Properties<space/></arg></template></extension><space/>Frequently prepared solid salts of amphetamine include amphetamine aspartate,<extension extension_name='ref' name="FDA Abuse &amp; OD"></extension><space/>hydrochloride,<extension extension_name='ref'><template><target>cite encyclopedia</target><arg name="title">Amphetamine Hydrochloride<space/></arg><arg name="url">http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid</arg><arg name="work"><space/>Pubchem Compound<space/></arg><arg name="publisher"><space/>National Center for Biotechnology Information<space/></arg><arg name="accessdate"><space/>8 November 2013</arg></template></extension><space/>phosphate,<extension extension_name='ref'><template><target>cite encyclopedia</target><arg name="title">Amphetamine Phosphate<space/></arg><arg name="url">http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid</arg><arg name="work">Pubchem Compound<space/></arg><arg name="publisher"><space/>National Center for Biotechnology Information<space/></arg><arg name="accessdate">8 November 2013</arg></template></extension><space/>saccharate,<extension extension_name='ref' name="FDA Abuse &amp; OD"></extension><space/>and sulfate,<extension extension_name='ref' name="FDA Abuse &amp; OD"></extension><space/>the last of which is the most common amphetamine salt.<extension extension_name='ref' name="EMC"></extension><space/>Amphetamine is also the parent compound of<space/><link><target>Substituted amphetamine</target><part>its own structural class</part></link>, which includes a number of psychoactive<space/><link><target>derivative (chemistry)</target><part>derivatives</part></link>.<extension extension_name='ref' name="Substituted amphetamines, FMO, and DBH"></extension><extension extension_name='ref' name="DrugBank1"></extension><space/>In organic chemistry, amphetamine is an excellent<space/><link><target>chiral ligand</target></link><space/>for the<space/><link><target>stereoselective synthesis</target></link><space/>of<space/><template><target>nowrap</target><arg>[[1,1'-bi-2-naphthol]]</arg></template>.<extension extension_name='ref' name="Chiral Ligand"><template><target>cite journal</target><arg name="author"><space/>Brussee J, Jansen ACA<space/></arg><arg name="date"><space/>May 1983<space/></arg><arg name="title"><space/>A highly stereoselective synthesis of s(−)-[1,1'-binaphthalene]-2,2'-diol<space/></arg><arg name="journal"><space/>Tetrahedron Lett.<space/></arg><arg name="volume"><space/>24<space/></arg><arg name="issue"><space/>31<space/></arg><arg name="pages"><space/>3261–3262<space/></arg><arg name="doi"><space/>10.1016/S0040-4039(00)88151-4<space/></arg></template></extension></paragraph><heading level='3'>Derivatives</heading><paragraph><template><target>Main list</target><arg>Substituted amphetamine</arg></template></paragraph><paragraph>Amphetamine derivatives, often referred to as &quot;amphetamines&quot; or &quot;substituted amphetamines&quot;, are a broad range of chemicals that contain amphetamine as a &quot;backbone&quot;;<extension extension_name='ref' name="Substituted amphetamines, FMO, and DBH"></extension><extension extension_name='ref' name="DrugBank Header"><template><target>cite encyclopedia</target><arg name="title">Amphetamine<space/></arg><arg name="section-url">http://www.drugbank.ca/drugs/DB00182<space/></arg><arg name="work">DrugBank<space/></arg><arg name="publisher"><space/>University of Alberta<space/></arg><arg name="accessdate">30 September 2013<space/></arg><arg name="date">8 February 2013<space/></arg><arg name="section">Compound Summary<space/></arg></template></extension><extension extension_name='ref' name="Schep"><template><target>cite journal</target><arg name="author">Schep LJ, Slaughter RJ, Beasley DM<space/></arg><arg name="title">The clinical toxicology of metamfetamine<space/></arg><arg name="journal">Clin. Toxicol. (Phila.)<space/></arg><arg name="volume">48<space/></arg><arg name="issue">7<space/></arg><arg name="pages">675–694<space/></arg><arg name="date">August 2010<space/></arg><arg name="pmid">20849327<space/></arg><arg name="doi">10.3109/15563650.2010.516752<space/></arg><arg name="issn">1556-3650</arg></template></extension><space/>specifically, this<space/><link><target>Chemical classification</target><part>chemical class</part></link><space/>includes<space/><link><target>derivative (chemistry)</target><part>derivative</part></link><space/>compounds that are formed by replacing one or more hydrogen atoms in the amphetamine core structure with<space/><link><target>substituent</target><trail>s</trail></link>.<extension extension_name='ref' name="Substituted amphetamines, FMO, and DBH"></extension><extension extension_name='ref' name="pmid1855720"><template><target>cite journal</target><arg name="vauthors"><space/>Lillsunde P, Korte T<space/></arg><arg name="title"><space/>Determination of ring- and N-substituted amphetamines as heptafluorobutyryl derivatives<space/></arg><arg name="journal"><space/>Forensic Sci. Int.<space/></arg><arg name="volume"><space/>49<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>205–213<space/></arg><arg name="date"><space/>March 1991<space/></arg><arg name="pmid"><space/>1855720<space/></arg></template></extension><space/>The class includes stimulants like methamphetamine, serotonergic<space/><link><target>empathogens</target></link><space/>like<space/><link><target>MDMA</target></link>, and<space/><link><target>decongestant</target><trail>s</trail></link><space/>like<space/><link><target>ephedrine</target></link>, among other subgroups.<extension extension_name='ref' name="Substituted amphetamines, FMO, and DBH"></extension><extension extension_name='ref' name="DrugBank Header"></extension><extension extension_name='ref' name="Schep"></extension></paragraph><heading level='3'>Synthesis</heading><paragraph><template><target>Details3</target><arg>[[History and culture of substituted amphetamines#Illegal synthesis|Illegal synthesis of substituted amphetamines]]</arg><arg>illicit amphetamine synthesis</arg></template></paragraph><paragraph>Since the first preparation was reported in 1887,<extension extension_name='ref' name="Vermont"></extension><space/>numerous synthetic routes to amphetamine have been developed.<extension extension_name='ref' name="Allen_Ely_2009"><template><target>cite journal</target><arg name="url"><space/>http://www.nwafs.org/newsletters/2011_Spring.pdf<space/></arg><arg name="title"><space/>Review: Synthetic Methods for Amphetamine<space/></arg><arg name="author"><space/>Allen A, Ely R<space/></arg><arg name="format"><space/>PDF<space/></arg><arg name="work"><space/></arg><arg name="publisher"><space/>Northwest Association of Forensic Scientists<space/></arg><arg name="volume"><space/>37<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="date"><space/>April 2009<space/></arg><arg name="pages"><space/>15–25<space/></arg><arg name="journal"><space/>Crime Scene<space/></arg><arg name="accessdate"><space/>6 December 2014</arg></template></extension><extension extension_name='ref' name="Allen_Cantrell_1989"><template><target>cite journal</target><arg name="author"><space/>Allen A, Cantrell TS<space/></arg><arg name="title"><space/>Synthetic reductions in clandestine amphetamine and methamphetamine laboratories: A review<space/></arg><arg name="journal"><space/>Forensic Science International<space/></arg><arg name="date"><space/>August 1989<space/></arg><arg name="volume"><space/>42<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>183–199<space/></arg><arg name="doi"><space/>10.1016/0379-0738(89)90086-8<space/></arg></template></extension><space/>The most common route of both legal and illicit amphetamine synthesis employs a non-metal reduction known as the<space/><link><target>Leuckart reaction</target></link><space/>(method 1).<extension extension_name='ref' name="EMC"></extension><extension extension_name='ref' name="Amph Synth"></extension><space/>In the first step, a reaction between phenylacetone and<space/><link><target>formamide</target></link>, either using additional<space/><link><target>formic acid</target></link><space/>or formamide itself as a reducing agent, yields<space/><template><target>nowrap</target><arg>[[N-formylamphetamine|''N''-formylamphetamine]]</arg></template>. This intermediate is then hydrolyzed using hydrochloric acid, and subsequently basified, extracted with organic solvent, concentrated, and distilled to yield the free base. The free base is then dissolved in an organic solvent, sulfuric acid added, and amphetamine precipitates out as the sulfate salt.<extension extension_name='ref' name="Amph Synth"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="doi"><space/>10.1021/jo01145a001<space/></arg><arg name="title"><space/>The Mechanism of the Leuckart Reaction<space/></arg><arg name="date">May 1951<space/></arg><arg name="author"><space/>Pollard CB, Young DC<space/></arg><arg name="journal"><space/>J. Org. Chem.<space/></arg><arg name="volume"><space/>16<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>661–672</arg></template></extension></paragraph><paragraph>A number of<space/><link><target>chiral resolution</target><trail>s</trail></link><space/>have been developed to separate the two enantiomers of amphetamine.<extension extension_name='ref' name="Allen_Ely_2009"></extension><space/>For example, racemic amphetamine can be treated with<space/><template><target>nowrap</target><arg>d-[[tartaric acid]]</arg></template><space/>to form a<space/><link><target>diastereoisomer</target><trail>ic</trail></link><space/>salt which is<space/><link><target>fractional crystallization (chemistry)</target><part>fractionally</part></link><space/>crystallized to yield dextroamphetamine.<extension extension_name='ref' name="US2276508"><template><target>cite patent</target><arg name="country"><space/>US<space/></arg><arg name="number"><space/>2276508<space/></arg><arg name="status"><space/>patent<space/></arg><arg name="title"><space/>Method for the separation of optically active alpha-methylphenethylamine<space/></arg><arg name="pubdate"><space/>17 March 1942<space/></arg><arg name="fdate"><space/>3 November 1939<space/></arg><arg name="pridate"><space/>3 November 1939<space/></arg><arg name="inventor"><space/>Nabenhauer FP<space/></arg><arg name="assign1"><space/>Smith Kline French<space/></arg></template></extension><space/>Chiral resolution remains the most economical method for obtaining optically pure amphetamine on a large scale.<extension extension_name='ref' name="Gray_2007"></extension><space/>In addition, several<space/><link><target>enantioselective synthesis</target><part>enantioselective</part></link><space/>syntheses of amphetamine have been developed. In one example,<space/><link><target>optically pure</target></link><space/><template><target>nowrap</target><arg>(''R'')-1-phenyl-ethanamine</arg></template><space/>is condensed with phenylacetone to yield a chiral<space/><link><target>Schiff base</target></link>. In the key step, this intermediate is reduced by<space/><link><target>catalytic hydrogenation</target></link><space/>with a transfer of chirality to the carbon atom alpha to the amino group. Cleavage of the<space/><link><target>benzylic</target></link><space/>amine bond by hydrogenation yields optically pure dextroamphetamine.<extension extension_name='ref' name="Gray_2007"><template><target>Cite book</target><arg name="editor"><space/>Johnson DS, Li JJ<space/></arg><arg name="author"><space/>Gray DL<space/></arg><arg name="title"><space/>The Art of Drug Synthesis<space/></arg><arg name="chapter"><space/>Approved Treatments for Attention Deficit Hyperactivity Disorder: Amphetamine (Adderall), Methylphenidate (Ritalin), and Atomoxetine (Straterra)<space/></arg><arg name="chapterurl"><space/>https://books.google.com/books?id</arg><arg name="year"><space/>2007<space/></arg><arg name="publisher"><space/>Wiley-Interscience<space/></arg><arg name="location"><space/>New York, USA<space/></arg><arg name="isbn"><space/>9780471752158<space/></arg><arg name="page"><space/>247<space/></arg></template></extension></paragraph><paragraph>A large number of alternative synthetic routes to amphetamine have been developed based on classic organic reactions.<extension extension_name='ref' name="Allen_Ely_2009"></extension><extension extension_name='ref' name="Allen_Cantrell_1989"></extension><space/>One example is the<space/><link><target>FriedelCrafts reaction#FriedelCrafts alkylation</target><part>FriedelCrafts</part></link><space/>alkylation of<space/><link><target>chlorobenzene</target></link><space/>by<space/><link><target>allyl chloride</target></link><space/>to yield beta chloropropylbenzene which is then reacted with ammonia to produce racemic amphetamine (method 2).<extension extension_name='ref' name="pmid20985610"><template><target>cite journal</target><arg name="author"><space/>Patrick TM, McBee ET, Hass HB<space/></arg><arg name="title"><space/>Synthesis of arylpropylamines; from allyl chloride<space/></arg><arg name="journal"><space/>J. Am. Chem. Soc.<space/></arg><arg name="volume"><space/>68<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>1009–1011<space/></arg><arg name="date"><space/>June 1946<space/></arg><arg name="pmid"><space/>20985610<space/></arg><arg name="doi"><space/>10.1021/ja01210a032<space/></arg></template></extension><space/>Another example employs the<space/><link><target>Ritter reaction</target></link><space/>(method 3). In this route,<space/><link><target>allylbenzene</target></link><space/>is reacted<space/><link><target>acetonitrile</target></link><space/>in sulfuric acid to yield an<space/><link><target>organosulfate</target></link><space/>which in turn is treated with sodium hydroxide to give amphetamine via an<space/><link><target>acetamide</target></link><space/>intermediate.<extension extension_name='ref' name="pmid18105933"><template><target>cite journal</target><arg name="author"><space/>Ritter JJ, Kalish J<space/></arg><arg name="title"><space/>A new reaction of nitriles; synthesis of t-carbinamines<space/></arg><arg name="journal"><space/>J. Am. Chem. Soc.<space/></arg><arg name="volume"><space/>70<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>4048–4050<space/></arg><arg name="date"><space/>December 1948<space/></arg><arg name="pmid"><space/>18105933<space/></arg><arg name="doi"><space/>10.1021/ja01192a023<space/></arg></template></extension><extension extension_name='ref' name="Krimen_Cota_1969"><template><target>cite journal</target><arg name="title">The Ritter Reaction</arg><arg name="author"><space/>Krimen LI, Cota DJ<space/></arg><arg name="journal"><space/>Organic Reactions<space/></arg><arg name="date"><space/>March 2011<space/></arg><arg name="volume"><space/>17<space/></arg><arg name="page"><space/>216<space/></arg><arg name="doi"><space/>10.1002/0471264180.or017.03</arg></template></extension><space/>A third route starts with<space/><template><target>nowrap</target><arg>[[ethyl acetoacetate|ethyl 3-oxobutanoate]]</arg></template><space/>which through a double alkylation with<space/><link><target>methyl iodide</target></link><space/>followed by<space/><link><target>benzyl chloride</target></link><space/>can be converted into<space/><template><target>nowrap</target><arg>2-methyl-3-phenyl-propanoic</arg></template><space/>acid. This synthetic intermediate can be transformed into amphetamine using either a<space/><link><target>Hofmann rearrangement</target><part>Hofmann</part></link><space/>or<space/><link><target>Curtius rearrangement</target></link><space/>(method 4).<extension extension_name='ref' name="US2413493"><template><target>cite patent</target><arg name="country"><space/>US<space/></arg><arg name="number"><space/>2413493<space/></arg><arg name="status"><space/>patent<space/></arg><arg name="title"><space/>Synthesis of isomer-free benzyl methyl acetoacetic methyl ester<space/></arg><arg name="pubdate"><space/>31 December 1946<space/></arg><arg name="fdate"><space/>3 June 1943<space/></arg><arg name="pridate"><space/>3 June 1943<space/></arg><arg name="inventor"><space/>Bitler WP, Flisik AC, Leonard N<space/></arg><arg name="assign1"><space/>Kay Fries Chemicals Inc<space/></arg></template></extension></paragraph><paragraph>A significant number of amphetamine syntheses feature a<space/><link><target>Organic redox reaction#Organic reductions</target><part>reduction</part></link><space/>of a<space/><link><target>nitro group</target><part>nitro</part></link>,<space/><link><target>imine</target></link>,<space/><link><target>oxime</target></link><space/>or other nitrogen-containing<space/><link><target>functional group</target><trail>s</trail></link>.<extension extension_name='ref' name="Allen_Cantrell_1989"></extension><space/>In one such example, a<space/><link><target>Knoevenagel condensation</target></link><space/>of<space/><link><target>benzaldehyde</target></link><space/>with<space/><link><target>nitroethane</target></link><space/>yields<space/><template><target>nowrap</target><arg>[[phenyl-2-nitropropene]]</arg></template>. The double bond and nitro group of this intermediate is<space/><link><target>organic redox reaction</target><part>reduced</part></link><space/>using either catalytic<space/><link><target>hydrogenation</target></link><space/>or by treatment with<space/><link><target>lithium aluminium hydride</target></link><space/>(method 5).<extension extension_name='ref' name="Amph Synth"><template><target>cite web</target><arg name="url"><space/>http://www.unodc.org/pdf/scientific/stnar34.pdf<space/></arg><arg name="title"><space/>Recommended methods of the identification and analysis of amphetamine, methamphetamine, and their ring-substituted analogues in seized materials<space/></arg><arg name="pages"><space/>9–12<space/></arg><arg name="accessdate"><space/>14 October 2013<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="work"><space/>United Nations Office on Drugs and Crime<space/></arg><arg name="publisher"><space/>United Nations</arg></template></extension><extension extension_name='ref' name="Delta Isotope"><template><target>cite journal</target><arg name="author"><space/>Collins M, Salouros H, Cawley AT, Robertson J, Heagney AC, Arenas-Queralt A<space/></arg><arg name="title"><space/>δ<sup>13</sup>C and δ<sup>2</sup>H isotope ratios in amphetamine synthesized from benzaldehyde and nitroethane<space/></arg><arg name="journal"><space/>Rapid Commun. Mass Spectrom.<space/></arg><arg name="volume"><space/>24<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1653–1658<space/></arg><arg name="date">June 2010<space/></arg><arg name="pmid"><space/>20486262<space/></arg><arg name="doi"><space/>10.1002/rcm.4563<space/></arg></template></extension><space/>Another method is the reaction of<space/><link><target>phenylacetone</target></link><space/>with<space/><link><target>ammonia</target></link>, producing an imine intermediate that is reduced to the primary amine using hydrogen over a palladium catalyst or lithium aluminum hydride (method 6).<extension extension_name='ref' name="Amph Synth"></extension></paragraph><table style="margin: 1em auto;"><tablerow style="vertical-align: top;"></tablerow><tablecaption><bold>Amphetamine synthetic routes</bold></tablecaption><tablerow><tablecell><table><tablerow><tablecell><template><target>multiple image</target><arg name="align"><space/>center
</arg><arg name="direction"><space/>vertical
</arg><arg name="width"><space/>372
<space/></arg><arg name="header">
</arg><arg name="header_align"><space/>center
</arg><arg name="header_background">
</arg><arg name="footer">
</arg><arg name="footer_align">
</arg><arg name="footer_background">
</arg><arg name="background color">

</arg><arg name="image1">Amphetamine Leukart synthesis.svg
</arg><arg name="caption1">Method 1: Synthesis by the Leuckart reaction<br />&nbsp;
</arg><arg name="alt1">Diagram of amphetamine synthesis by the Leuckart reaction

</arg><arg name="image2">Amphetamine resolution and chiral synthesis.svg
</arg><arg name="caption2">Top: Chiral resolution of amphetamine<space/><br />Bottom: Stereoselective synthesis of amphetamine
</arg><arg name="alt2">Diagram of a chiral resolution of racemic amphetamine and a stereoselective synthesis

</arg><arg name="image3">Amphetamine Friedel-Crafts alkylation.svg
</arg><arg name="caption3">Method 2: Synthesis by Friedel–Crafts alkylation
</arg><arg name="alt3">Diagram of amphetamine synthesis by Friedel–Crafts alkylation
</arg></template></tablecell></tablerow></table></tablecell><tablecell><table><tablerow><tablecell><template><target>multiple image</target><arg name="align"><space/>center
</arg><arg name="direction"><space/>vertical
</arg><arg name="width"><space/>372
<space/></arg><arg name="header">
</arg><arg name="header_align"><space/>center
</arg><arg name="header_background">
</arg><arg name="footer">
</arg><arg name="footer_align">
</arg><arg name="footer_background">
</arg><arg name="background color">
</arg><arg name="image1">Amphetamine Ritter Synthesis.svg
</arg><arg name="caption1">Method 3: Ritter synthesis
</arg><arg name="alt1">Diagram of amphetamine via Ritter synthesis
</arg><arg name="image2">Amphetamine Hofmann Curtius Synthesis.svg
</arg><arg name="caption2">Method 4: Synthesis via Hofmann and Curtius rearrangements
</arg><arg name="alt2">Diagram of amphetamine synthesis via Hofmann and Curtius rearrangements
</arg><arg name="image3">Amphetamine Knoevenagel synthesis.svg
</arg><arg name="caption3">Method 5: Synthesis by Knoevenagel condensation
</arg><arg name="alt3">Diagram of amphetamine synthesis by Knoevenagel condensation
</arg><arg name="image4">Amphetamine p2p ammonia synthesis.svg
</arg><arg name="caption4">Method 6: Synthesis using phenylacetone and ammonia
</arg><arg name="alt4">Diagram of amphetamine synthesis from phenylacetone and ammonia
</arg></template></tablecell></tablerow></table></tablecell></tablerow></table><paragraph><template><target>clear</target></template></paragraph><heading level='3'>Detection in body fluids</heading><paragraph>Amphetamine is frequently measured in urine or blood as part of a<space/><link><target>drug test</target></link><space/>for sports, employment, poisoning diagnostics, and forensics.#tag:ref Techniques such as<space/><link><target>immunoassay</target></link>, which is the most common form of amphetamine test, may cross-react with a number of sympathomimetic drugs.<extension extension_name='ref' name="NAHMSA_testing"></extension><space/>Chromatographic methods specific for amphetamine are employed to prevent false positive results.<extension extension_name='ref' name="pmid15516295"></extension><space/>Chiral separation techniques may be employed to help distinguish the source of the drug, whether prescription amphetamine, prescription amphetamine prodrugs, (e.g.,<space/><link><target>selegiline</target></link>),<space/><link><target>over-the-counter drug</target></link><space/>products (e.g., the American version of<space/><link><target>Vicks VapoInhaler</target></link>,<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid</arg><arg name="title">LABEL: VICKS VAPOINHALER- levmetamfetamine inhalant<space/></arg><arg name="publisher"><space/>National Institutes of Health, National Library of Medicine<space/></arg><arg name="work"><space/>DailyMed<space/></arg><arg name="date">June 2010<space/></arg><arg name="accessdate">3 April 2015</arg></template></extension><space/>which contains<space/><link><target>levomethamphetamine</target></link>) or illicitly obtained substituted amphetamines.<extension extension_name='ref' name="pmid15516295"><template><target>cite journal</target><arg name="author"><space/>Paul BD, Jemionek J, Lesser D, Jacobs A, Searles DA<space/></arg><arg name="title"><space/>Enantiomeric separation and quantitation of (±)-amphetamine, (±)-methamphetamine, (±)-MDA, (±)-MDMA, and (±)-MDEA in urine specimens by GC-EI-MS after derivatization with (''R'')-(−)- or (''S'')-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (MTPA)<space/></arg><arg name="journal"><space/>J. Anal. Toxicol.<space/></arg><arg name="volume"><space/>28<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>449–455<space/></arg><arg name="date">September 2004<space/></arg><arg name="pmid"><space/>15516295<space/></arg><arg name="doi"><space/>10.1093/jat/28.6.449<space/></arg></template></extension><extension extension_name='ref' name="pmid16105261"><template><target>cite journal</target><arg name="author"><space/>Verstraete AG, Heyden FV<space/></arg><arg name="title"><space/>Comparison of the sensitivity and specificity of six immunoassays for the detection of amphetamines in urine<space/></arg><arg name="journal"><space/>J. Anal. Toxicol.<space/></arg><arg name="volume"><space/>29<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>359–364<space/></arg><arg name="date"><space/>August 2005<space/></arg><arg name="pmid"><space/>16105261<space/></arg><arg name="doi">10.1093/jat/29.5.359<space/></arg></template></extension><extension extension_name='ref' name="Baselt_2011"><template><target>cite book</target><arg name="author"><space/>Baselt RC<space/></arg><arg name="title"><space/>Disposition of Toxic Drugs and Chemicals in Man<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="publisher"><space/>Biomedical Publications<space/></arg><arg name="location">Seal Beach, USA<space/></arg><arg name="isbn"><space/>9780962652387<space/></arg><arg name="pages"><space/>85–88<space/></arg><arg name="edition"><space/>9th<space/></arg></template></extension><space/>Several prescription drugs produce amphetamine as a<space/><link><target>metabolite</target></link>, including<space/><link><target>benzphetamine</target></link>,<space/><link><target>clobenzorex</target></link>,<space/><link><target>famprofazone</target></link>,<space/><link><target>fenproporex</target></link>,<space/><link><target>lisdexamfetamine</target></link>,<space/><link><target>mesocarb</target></link>, methamphetamine,<space/><link><target>prenylamine</target></link>, and<space/><link><target>selegiline</target></link>, among others.<extension extension_name='ref' name="Amph Uses"></extension><extension extension_name='ref' name="pmid10711406"><template><target>cite journal</target><arg name="author"><space/>Musshoff F<space/></arg><arg name="title"><space/>Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine<space/></arg><arg name="journal"><space/>Drug Metab. Rev.<space/></arg><arg name="volume"><space/>32<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>15–44<space/></arg><arg name="date">February 2000<space/></arg><arg name="pmid"><space/>10711406<space/></arg><arg name="doi"><space/>10.1081/DMR-100100562<space/></arg></template></extension><extension extension_name='ref' name="pmid12024689"><template><target>cite journal</target><arg name="author"><space/>Cody JT<space/></arg><arg name="title"><space/>Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results<space/></arg><arg name="journal"><space/>J. Occup. Environ. Med.<space/></arg><arg name="volume"><space/>44<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>435–450<space/></arg><arg name="date">May 2002<space/></arg><arg name="pmid"><space/>12024689<space/></arg><arg name="doi"><space/>10.1097/00043764-200205000-00012<space/></arg></template></extension><space/>These compounds may produce positive results for amphetamine on drug tests.<extension extension_name='ref' name="pmid10711406"></extension><extension extension_name='ref' name="pmid12024689"></extension><space/>Amphetamine is generally only detectable by a standard drug test for approximately 24&amp;nbsp;hours, although a high dose may be detectable for two to four days.<extension extension_name='ref' name="NAHMSA_testing"><template><target>cite web</target><arg name="title">Clinical Drug Testing in Primary Care<space/></arg><arg name="url">http://162.99.3.213/products/manuals/pdfs/TAP32.pdf<space/></arg><arg name="work">Substance Abuse and Mental Health Services Administration<space/></arg><arg name="publisher">United States Department of Health and Human Services<space/></arg><arg name="series">Technical Assistance Publication Series 32<space/></arg><arg name="year">2012<space/></arg><arg name="accessdate">31 October 2013</arg></template></extension></paragraph><paragraph>For the assays, a study noted that an<space/><link><target>enzyme multiplied immunoassay technique</target></link><space/>(EMIT) assay for amphetamine and methamphetamine may produce more false positives than<space/><link><target>Liquid chromatographymass spectrometry#Proteomics/metabolomics</target><part>liquid chromatographytandem mass spectrometry</part></link>.<extension extension_name='ref' name="pmid16105261"></extension><space/><link><target>Gas chromatographymass spectrometry</target></link><space/>(GCMS) of amphetamine and methamphetamine with the derivatizing agent<space/><template><target>nowrap</target><arg>(''S'')-(−)-trifluoroacetylprolyl</arg></template><space/>chloride allows for the detection of methamphetamine in urine.<extension extension_name='ref' name="pmid15516295"></extension><space/>GCMS of amphetamine and methamphetamine with the chiral derivatizing agent<space/><link><target>Mosher's acid</target><part>Mosher's&amp;nbsp;acid chloride</part></link><space/>allows for the detection of both dextroamphetamine and dextromethamphetamine in urine.<extension extension_name='ref' name="pmid15516295"></extension><space/>Hence, the latter method may be used on samples that test positive using other methods to help distinguish between the various sources of the drug.<extension extension_name='ref' name="pmid15516295"></extension></paragraph><heading level='2'>History, society, and culture</heading><paragraph><template><target>Main</target><arg>History and culture of substituted amphetamines</arg></template><template><target>Global estimates of illicit drug users</target></template></paragraph><paragraph>Amphetamine was first synthesized in 1887 in Germany by Romanian chemist<space/><link><target>Lazr Edeleanu</target></link><space/>who named it<space/><italics>phenylisopropylamine</italics>;<extension extension_name='ref' name="Vermont"><template><target>cite web</target><arg name="url">http://healthvermont.gov/adap/meth/brief_history.aspx<space/></arg><arg name="title">Historical overview of methamphetamine<space/></arg><arg name="work">Vermont Department of Health<space/></arg><arg name="publisher">Government of Vermont<space/></arg><arg name="accessdate">29 January 2012</arg></template></extension><extension extension_name='ref'><template><target>cite book</target><arg name="author"><space/>Rassool GH<space/></arg><arg name="title">Alcohol and Drug Misuse: A Handbook for Students and Health Professionals<space/></arg><arg name="year">2009<space/></arg><arg name="publisher">Routledge<space/></arg><arg name="location">London, England<space/></arg><arg name="isbn">9780203871171<space/></arg><arg name="page">113</arg></template></extension><extension extension_name='ref' name="SynthHistory"></extension><space/>its stimulant effects remained unknown until 1927, when it was independently resynthesized by Gordon Alles and reported to have<space/><link><target>sympathomimetic</target></link><space/>properties.<extension extension_name='ref' name="SynthHistory"><template><target>cite journal</target><arg name="author">Sulzer D, Sonders MS, Poulsen NW, Galli A<space/></arg><arg name="title">Mechanisms of neurotransmitter release by amphetamines: a review<space/></arg><arg name="journal">Prog. Neurobiol.<space/></arg><arg name="volume">75<space/></arg><arg name="issue">6<space/></arg><arg name="pages">406–433<space/></arg><arg name="date">April 2005<space/></arg><arg name="pmid">15955613<space/></arg><arg name="doi">10.1016/j.pneurobio.2005.04.003<space/></arg><arg name="url"></arg></template></extension><space/>Amphetamine had no pharmacological use until 1934, when<space/><link><target>Smith, Kline and French</target></link><space/>began selling it as an<space/><link><target>inhaler</target></link><space/>under the trade name<space/><link><target>Benzedrine</target></link><space/>as a decongestant.<extension extension_name='ref' name="Benzedrine"><template><target>cite journal</target><arg name="author">Rasmussen N<space/></arg><arg name="title">Making the first anti-depressant: amphetamine in American medicine, 1929–1950<space/></arg><arg name="journal">J . Hist. Med. Allied Sci.<space/></arg><arg name="volume">61<space/></arg><arg name="issue">3<space/></arg><arg name="pages">288–323<space/></arg><arg name="date">July 2006<space/></arg><arg name="pmid">16492800<space/></arg><arg name="doi">10.1093/jhmas/jrj039</arg></template></extension><space/>During World War II, amphetamine and methamphetamine were used extensively by both the Allied and Axis forces for their stimulant and performance-enhancing effects.<extension extension_name='ref' name="Vermont"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Rasmussen N<space/></arg><arg name="title">Medical science and the military: the Allies' use of amphetamine during World War II<space/></arg><arg name="journal">J. Interdiscip. Hist.<space/></arg><arg name="date">August 2011<space/></arg><arg name="volume">42<space/></arg><arg name="issue">2<space/></arg><arg name="pages">205–233<space/></arg><arg name="pmid">22073434<space/></arg><arg name="doi">10.1162/JINH_a_00212<space/></arg></template></extension><extension extension_name='ref' name="pmid22849208"><template><target>cite journal</target><arg name="author"><space/>Defalque RJ, Wright AJ<space/></arg><arg name="title"><space/>Methamphetamine for Hitler's Germany: 1937 to 1945<space/></arg><arg name="journal"><space/>Bull. Anesth. Hist.<space/></arg><arg name="volume"><space/>29<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>21–24, 32<space/></arg><arg name="date">April 2011<space/></arg><arg name="pmid"><space/>22849208<space/></arg><arg name="doi"><space/></arg></template></extension><space/>As the addictive properties of the drug became known, governments began to place strict controls on the sale of amphetamine.<extension extension_name='ref' name="Vermont"></extension><space/>For example, during the early 1970s in the United States, amphetamine became a<space/><link><target>Schedule II (US)</target><part>schedule II controlled substance</part></link><space/>under the<space/><link><target>Controlled Substances Act</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Controlled Substances Act<space/></arg><arg name="url">http://www.fda.gov/regulatoryinformation/legislation/ucm148726.htm<space/></arg><arg name="publisher">United States Food and Drug Administration<space/></arg><arg name="date">11 June 2009<space/></arg><arg name="accessdate">4 November 2013</arg></template></extension><space/>In spite of strict government controls, amphetamine has been used legally or illicitly by people from a variety of backgrounds, including authors,<extension extension_name='ref'><template><target>cite web</target><arg name="author"><space/>Gyenis A<space/></arg><arg name="work"><space/>wordsareimportant.com<space/></arg><arg name="publisher"><space/>DHARMA beat<space/></arg><arg name="title"><space/>Forty Years of ''On the Road'' 1957–1997</arg><arg name="url"><space/>http://www.wordsareimportant.com/ontheroad.htm<space/></arg><arg name="accessdate"><space/>18 March 2008<space/></arg><arg name="archiveurl"><space/>https://web.archive.org/web/20080214171739/http://www.wordsareimportant.com/ontheroad.htm<space/></arg><arg name="archivedate"><space/>14 February 2008</arg></template></extension><space/>musicians,<extension extension_name='ref'><template><target>cite web</target><arg name="title"><space/>Mixing the Medicine: The unintended consequence of amphetamine control on the Northern Soul Scene<space/></arg><arg name="author"><space/>Wilson A<space/></arg><arg name="url"><space/>http://www.internetjournalofcriminology.com/Wilson%20-%20Mixing%20the%20Medicine.pdf<space/></arg><arg name="publisher"><space/>Internet Journal of Criminology<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="accessdate">25 May 2013<space/></arg></template></extension><space/>mathematicians,<extension extension_name='ref'><template><target>cite web</target><arg name="title"><space/>Paul Erdos, Mathematical Genius, Human (In That Order)<space/></arg><arg name="url"><space/>http://www.untruth.org/~josh/math/Paul%20Erd%F6s%20bio-rev2.pdf<space/></arg><arg name="author"><space/>Hill J<space/></arg><arg name="accessdate"><space/>2 November 2013<space/></arg><arg name="date"><space/>4 June 2004</arg></template></extension><space/>and athletes.<extension extension_name='ref' name="Ergogenics"></extension></paragraph><paragraph>Amphetamine is still illegally synthesized today in<space/><link><target>clandestine chemistry</target><part>clandestine labs</part></link><space/>and sold on the<space/><link><target>black market</target></link>, primarily in European countries.<extension extension_name='ref' name="WDR2014"><template><target>cite web</target><arg name="title"><space/>World Drug Report 2014<space/></arg><arg name="editor"><space/>Mohan J<space/></arg><arg name="date"><space/>June 2014<space/></arg><arg name="page"><space/>3<space/></arg><arg name="work"><space/>United Nations Office on Drugs and Crime<space/></arg><arg name="url"><space/>https://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf<space/></arg><arg name="accessdate"><space/>18 August 2014<space/></arg></template></extension><space/>Among European Union (EU) member states, 1.2&amp;nbsp;million young adults used illicit amphetamine or methamphetamine in 2013.<extension extension_name='ref' name="EMCDDA 2014"><template><target>cite journal</target><arg name="title">European drug report 2014: Trends and developments<space/></arg><arg name="date">May 2014<space/></arg><arg name="pages">13, 24<space/></arg><arg name="doi">10.2810/32306<space/></arg><arg name="url">http://www.emcdda.europa.eu/attachements.cfm/att_228272_EN_TDAT14001ENN.pdf<space/></arg><arg name="accessdate">18 August 2014<space/></arg><arg name="publisher">European Monitoring Centre for Drugs and Drug Addiction<space/></arg><arg name="location">Lisbon, Portugal<space/></arg><arg name="format">PDF<space/></arg><arg name="issn">2314-9086<space/></arg><arg name="quote">1.2 million or 0.9% of young adults (15–34) used amphetamines in the last year</arg></template></extension><space/>During 2012, approximately 5.9&amp;nbsp;<link><target>metric ton</target><trail>s</trail></link><space/>of illicit amphetamine were seized within EU member states;<extension extension_name='ref' name="EMCDDA 2014"></extension><space/>the &quot;street price&quot; of illicit amphetamine within the EU ranged from 638&amp;nbsp;per gram during the same period.<extension extension_name='ref' name="EMCDDA 2014"></extension><space/>Outside Europe, the illicit market for amphetamine is much smaller than the market for methamphetamine and MDMA.<extension extension_name='ref' name="WDR2014"></extension></paragraph><heading level='3'>Legal status</heading><paragraph>As a result of the<space/><link><target>United Nations</target></link><space/>1971<space/><link><target>Convention on Psychotropic Substances</target></link>, amphetamine became a schedule II controlled substance, as defined in the treaty, in all (183) state parties.<extension extension_name='ref' name="UN Convention"><template><target>cite web</target><arg name="title">Convention on psychotropic substances<space/></arg><arg name="url">http://treaties.un.org/Pages/ViewDetails.aspx?src</arg><arg name="work">United Nations Treaty Collection<space/></arg><arg name="publisher">United Nations<space/></arg><arg name="accessdate">11 November 2013</arg></template></extension><space/>Consequently, it is heavily regulated in most countries.<extension extension_name='ref' name="UNODC2007"><template><target>cite book</target><arg name="author"><space/>United Nations Office on Drugs and Crime<space/></arg><arg name="title"><space/>Preventing Amphetamine-type Stimulant Use Among Young People: A Policy and Programming Guide<space/></arg><arg name="publisher"><space/>United Nations<space/></arg><arg name="location"><space/>New York, USA<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="isbn"><space/>9789211482232<space/></arg><arg name="url"><space/>http://www.unodc.org/pdf/youthnet/ATS.pdf<space/></arg><arg name="accessdate"><space/>11 November 2013</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="title"><space/>List of psychotropic substances under international control<space/></arg><arg name="work"><space/>International Narcotics Control Board<space/></arg><arg name="publisher"><space/>United Nations<space/></arg><arg name="url"><space/>http://www.incb.org/pdf/e/list/green.pdf<space/></arg><arg name="accessdate"><space/>19 November 2005<space/></arg><arg name="archiveurl"><space/>https://web.archive.org/web/20051205125434/http://www.incb.org/pdf/e/list/green.pdf<space/></arg><arg name="archivedate"><space/>5 December 2005<space/></arg><arg name="date">August 2003</arg></template></extension><space/>Some countries, such as South Korea and Japan, have banned substituted amphetamines even for medical use.<extension extension_name='ref' name="urlMoving to Korea brings medical, social changes"><template><target>cite web</target><arg name="url"><space/>https://www.koreatimes.co.kr/www/news/nation/2012/10/319_111757.html<space/></arg><arg name="title"><space/>Moving to Korea brings medical, social changes<space/></arg><arg name="work"><space/>The Korean Times<space/></arg><arg name="date"><space/>25 May 2012<space/></arg><arg name="accessdate"><space/>14 November 2013<space/></arg><arg name="author"><space/>Park Jin-seng</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.mhlw.go.jp/english/topics/import/<space/></arg><arg name="title"><space/>Importing or Bringing Medication into Japan for Personal Use<space/></arg><arg name="work"><space/>Japanese Ministry of Health, Labour and Welfare<space/></arg><arg name="accessdate">3 November 2013<space/></arg><arg name="date">1 April 2004</arg></template></extension><space/>In other nations, such as Canada (<link><target>Controlled Drugs and Substances Act</target><part>schedule I drug</part></link>),<extension extension_name='ref' name="Canada Control"><template><target>cite web</target><arg name="url"><space/>http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-24.html#h-28<space/></arg><arg name="title"><space/>Controlled Drugs and Substances Act<space/></arg><arg name="work"><space/>Canadian Justice Laws Website<space/></arg><arg name="publisher"><space/>Government of Canada<space/></arg><arg name="accessdate"><space/>11 November 2013<space/></arg></template></extension><space/>the Netherlands (<link><target>Opium Law</target><part>List I drug</part></link>),<extension extension_name='ref' name="Opiumwet"><template><target>cite web</target><arg name="url"><space/>http://wetten.overheid.nl/BWBR0001941/geldigheidsdatum_03-08-2009<space/></arg><arg name="title"><space/>Opiumwet<space/></arg><arg name="publisher"><space/>Government of the Netherlands<space/></arg><arg name="accessdate"><space/>3 April 2015<space/></arg></template></extension><space/>(Dutch) the United States (<link><target>Schedule II (US)</target><part>schedule II drug</part></link>),<extension extension_name='ref' name="FDA Abuse &amp; OD"></extension><space/>Thailand (<link><target>Law of Thailand#Criminal Law</target><part>category 1 narcotic</part></link>),<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://narcotic.fda.moph.go.th/faq/upload/Thai%20Narcotic%20Act%202012.doc._37ef.pdf<space/></arg><arg name="archiveurl">https://web.archive.org/web/20140308001155/http://narcotic.fda.moph.go.th/faq/upload/Thai%20Narcotic%20Act%202012.doc._37ef.pdf<space/></arg><arg name="title"><space/>Table of controlled Narcotic Drugs under the Thai Narcotics Act<space/></arg><arg name="work"><space/>Thailand Food and Drug Administration<space/></arg><arg name="date"><space/>22 May 2013<space/></arg><arg name="accessdate"><space/>11 November 2013<space/></arg><arg name="archivedate">8 March 2014<space/></arg></template></extension><space/>and United Kingdom (<link><target>Misuse of Drugs Act 1971</target><part>class B drug</part></link>),<extension extension_name='ref'><template><target>cite web</target><arg name="title"><space/>Class A, B and C drugs<space/></arg><arg name="work"><space/>Home Office, Government of the United Kingdom<space/></arg><arg name="url"><space/>http://www.homeoffice.gov.uk/drugs/drugs-law/Class-a-b-c/<space/></arg><arg name="accessdate"><space/>23 July 2007<space/></arg><arg name="archiveurl"><space/>http://web.archive.org/web/20070804233232/http://www.homeoffice.gov.uk/drugs/drugs-law/Class-a-b-c/<space/></arg><arg name="archivedate"><space/>4 August 2007<space/></arg></template></extension><space/>amphetamine is in a restrictive national drug schedule that allows for its use as a medical treatment.<extension extension_name='ref' name="WDR2014"></extension><extension extension_name='ref' name="Nonmedical"><template><target>cite journal</target><arg name="author"><space/>Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S<space/></arg><arg name="title"><space/>Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature<space/></arg><arg name="journal"><space/>J. Am. Acad. Child Adolesc. Psychiatry<space/></arg><arg name="volume"><space/>47<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>21–31<space/></arg><arg name="date">January 2008<space/></arg><arg name="pmid"><space/>18174822<space/></arg><arg name="doi"><space/>10.1097/chi.0b013e31815a56f1<space/></arg><arg name="quote">Stimulant misuse appears to occur both for performance enhancement and their euphorogenic effects, the latter being related to the intrinsic properties of the stimulants (e.g., IR versus ER profile)&nbsp;...<br /><br />Although useful in the treatment of ADHD, stimulants are controlled II substances with a history of preclinical and human studies showing potential abuse liability.</arg></template></extension></paragraph><heading level='3'>Pharmaceutical products</heading><paragraph>Two currently prescribed amphetamine formulations that contain both enantiomers are Adderall and Evekeo, the latter of which is racemic amphetamine sulfate.<extension extension_name='ref' name="Amph Uses"></extension><extension extension_name='ref' name="Evekeo"></extension><extension extension_name='ref' name="Racemic amph - FDA Evekeo status"></extension><space/>Amphetamine is also prescribed in<space/><link><target>Enantiopure drug</target><part>enantiopure</part></link><space/>and<space/><link><target>prodrug</target></link><space/>form as dextroamphetamine and lisdexamfetamine respectively.<extension extension_name='ref' name="NDCD"></extension><extension extension_name='ref' name="Vyvanse"></extension><space/>Lisdexamfetamine is structurally different from amphetamine, and is inactive until it metabolizes into dextroamphetamine.<extension extension_name='ref' name="Vyvanse"></extension><space/>The free base of racemic amphetamine was previously available as Benzedrine, Psychedrine, and Sympatedrine.<extension extension_name='ref' name="Amph Uses"></extension><space/>Levoamphetamine was previously available as Cydril.<extension extension_name='ref' name="Amph Uses"></extension><space/>All current amphetamine pharmaceuticals are<space/><link><target>salt (chemistry)</target><part>salts</part></link><space/>due to the comparatively high volatility of the free base.<extension extension_name='ref' name="Amph Uses"></extension><extension extension_name='ref' name="NDCD"></extension><extension extension_name='ref' name="EMC"></extension><space/>Some of the current brands and their generic equivalents are listed below.</paragraph><preblock><preline><table style="width: 90%"><tablerow><tablecell><table class="wikitable sortable" style="text-align:center; width:500px;"><tablecaption>Amphetamine pharmaceuticals</tablecaption><tablerow><tablehead scope="col">Brand<xhtml:br></xhtml:br>name</tablehead><tablehead scope="col"><link><target>United States Adopted Name</target><part>United States<xhtml:br></xhtml:br>Adopted Name</part></link></tablehead><tablehead scope="col" class="unsortable" style="text-align:center"><link><target>wikt:enantiomeric ratio</target><part>(D:L) ratio</part></link><xhtml:br></xhtml:br>of salts</tablehead><tablehead scope="col">Dosage<xhtml:br></xhtml:br>form</tablehead><tablehead scope="col" class="unsortable"><xhtml:small>Source</xhtml:small></tablehead></tablerow><tablerow><tablecell>Adderall</tablecell><tablecell></tablecell><tablecell>3:1</tablecell><tablecell>tablet</tablecell><tablecell><extension extension_name='ref' name="Amph Uses"></extension><extension extension_name='ref' name="NDCD"></extension></tablecell></tablerow><tablerow><tablecell>Adderall&amp;nbsp;XR</tablecell><tablecell></tablecell><tablecell>3:1</tablecell><tablecell>capsule</tablecell><tablecell><extension extension_name='ref' name="Amph Uses"></extension><extension extension_name='ref' name="NDCD"></extension></tablecell></tablerow><tablerow><tablecell>Evekeo</tablecell><tablecell>amphetamine sulfate</tablecell><tablecell>1:1</tablecell><tablecell>tablet</tablecell><tablecell><extension extension_name='ref' name="Evekeo"><template><target>cite web</target><arg name="title">Evekeo Prescribing Information<space/></arg><arg name="url">https://www.evekeo.com/assets/evekeo-pi.pdf<space/></arg><arg name="publisher">Arbor Pharmaceuticals LLC<space/></arg><arg name="accessdate">11 August 2015<space/></arg><arg name="pages">1–2<space/></arg><arg name="date">April 2014</arg></template></extension><extension extension_name='ref' name="Racemic amph - FDA Evekeo status"><template><target>cite web</target><arg name="title">Evekeo<space/></arg><arg name="url">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction</arg><arg name="website">United States Food and Drug Administration<space/></arg><arg name="accessdate">11 August 2015</arg></template></extension></tablecell></tablerow><tablerow><tablecell>Dexedrine</tablecell><tablecell>dextroamphetamine sulfate</tablecell><tablecell>1:0</tablecell><tablecell>capsule</tablecell><tablecell><extension extension_name='ref' name="Amph Uses"></extension><extension extension_name='ref' name="NDCD"></extension></tablecell></tablerow><tablerow><tablecell>ProCentra</tablecell><tablecell>dextroamphetamine sulfate</tablecell><tablecell>1:0</tablecell><tablecell>liquid</tablecell><tablecell><extension extension_name='ref' name="NDCD"></extension></tablecell></tablerow><tablerow><tablecell>Zenzedi</tablecell><tablecell>dextroamphetamine sulfate</tablecell><tablecell>1:0</tablecell><tablecell>tablet</tablecell><tablecell><extension extension_name='ref' name="NDCD"></extension></tablecell></tablerow><tablerow><tablecell>Vyvanse</tablecell><tablecell>lisdexamfetamine dimesylate</tablecell><tablecell>1:0</tablecell><tablecell>capsule</tablecell><tablecell><extension extension_name='ref' name="Amph Uses"><template><target>cite journal</target><arg name="author"><space/>Heal DJ, Smith SL, Gosden J, Nutt DJ<space/></arg><arg name="title"><space/>Amphetamine, past and present – a pharmacological and clinical perspective<space/></arg><arg name="journal"><space/>J. Psychopharmacol.<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>479–496<space/></arg><arg name="date">June 2013<space/></arg><arg name="pmid"><space/>23539642<space/></arg><arg name="pmc"><space/>3666194<space/></arg><arg name="doi"><space/>10.1177/0269881113482532</arg></template></extension><extension extension_name='ref' name="Vyvanse"><template><target>cite encyclopedia</target><arg name="title">Lisdexamfetamine<space/></arg><arg name="section-url">http://www.drugbank.ca/drugs/DB01255#identification<space/></arg><arg name="work">Drugbank<space/></arg><arg name="publisher"><space/>University of Alberta<space/></arg><arg name="accessdate">13 October 2013<space/></arg><arg name="date">8 February 2013<space/></arg><arg name="section">Identification<space/></arg></template></extension></tablecell></tablerow></table></tablecell><tablecell><table><tablecaption>&amp;nbsp;</tablecaption><tablerow><tablecell><link><target>File:Lisdexamfetamine-Structural Formula V.1.svg</target><part>thumb</part><part>left</part><part>The skeletal structure of lisdexamfetamine</part><part>alt=An image of the lisdexamfetamine compound</part></link></tablecell></tablerow></table></tablecell></tablerow></table><table class="wikitable"><tablecaption>Amphetamine base in marketed amphetamine medications</tablecaption><tablerow><tablehead colspan="2" rowspan="3">drug</tablehead><tablehead rowspan="3">formula</tablehead><tablehead colspan="2"><link><target>Molecular mass</target><part>molecular weight</part></link><xhtml:br></xhtml:br>#tag:ref</tablehead><tablehead colspan="3">amphetamine base<xhtml:br></xhtml:br>#tag:ref</tablehead><tablehead colspan="2">amphetamine base<xhtml:br></xhtml:br>equivalence</tablehead></tablerow><tablerow><tablehead colspan="2"><template><target>nobold</target><arg>(g/mol)</arg></template></tablehead><tablehead colspan="3"><template><target>nobold</target><arg>(percent)</arg></template></tablehead><tablehead colspan="2"><template><target>nobold</target><arg>(30&nbsp;mg dose)</arg></template></tablehead></tablerow><tablerow><tablehead>total</tablehead><tablehead>base</tablehead><tablehead>total</tablehead><tablehead>dextro-</tablehead><tablehead>levo-</tablehead><tablehead>dextro-</tablehead><tablehead>levo-</tablehead></tablerow><tablerow><tablecell colspan="2"><bold>amphetamine sulfate</bold><extension extension_name='ref' name="Amph sulfate mass"></extension></tablecell><tablecell>(C<xhtml:sub>9</xhtml:sub>H<xhtml:sub>13</xhtml:sub>N)<xhtml:sub>2</xhtml:sub><template><target>bull</target></template>H<xhtml:sub>2</xhtml:sub>SO<xhtml:sub>4</xhtml:sub></tablecell><tablecell><xhtml:center>368.49</xhtml:center></tablecell><tablecell><xhtml:center>270.41</xhtml:center></tablecell><tablecell><xhtml:center>73.4%</xhtml:center></tablecell><tablecell><xhtml:center>36.7%</xhtml:center></tablecell><tablecell><xhtml:center>36.7%</xhtml:center></tablecell><tablecell><xhtml:center>11.0&amp;nbsp;mg</xhtml:center></tablecell><tablecell><xhtml:center>11.0&amp;nbsp;mg</xhtml:center></tablecell></tablerow><tablerow><tablehead colspan="10"></tablehead></tablerow><tablerow><tablecell colspan="2"><bold>dextroamphetamine sulfate</bold><extension extension_name='ref' name="damph1"><template><target>Cite web</target><arg name="date"><space/>March 2014<space/></arg><arg name="title"><space/>Dextroamphetamine Sulfate USP<space/></arg><arg name="publisher"><space/>Mallinckrodt Pharmaceuticals<space/></arg><arg name="url">http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id</arg><arg name="accessdate"><space/>19 August 2015<space/></arg></template></extension><extension extension_name='ref' name="damph2"><template><target>Cite web</target><arg name="date"><space/>2015<space/></arg><arg name="title"><space/>D-amphetamine sulfate<space/></arg><arg name="publisher"><space/>Tocris<space/></arg><arg name="url">http://www.tocris.com/dispprod.php?ItemId</arg><arg name="accessdate"><space/>19 August 2015</arg></template></extension></tablecell><tablecell>(C<xhtml:sub>9</xhtml:sub>H<xhtml:sub>13</xhtml:sub>N)<xhtml:sub>2</xhtml:sub><template><target>bull</target></template>H<xhtml:sub>2</xhtml:sub>SO<xhtml:sub>4</xhtml:sub></tablecell><tablecell><xhtml:center>368.49</xhtml:center></tablecell><tablecell><xhtml:center>270.41</xhtml:center></tablecell><tablecell><xhtml:center>73.4%</xhtml:center></tablecell><tablecell><xhtml:center>73.4%</xhtml:center></tablecell><tablecell><xhtml:center></xhtml:center></tablecell><tablecell><xhtml:center>22.0&amp;nbsp;mg</xhtml:center></tablecell><tablecell><xhtml:center></xhtml:center></tablecell></tablerow><tablerow><tablehead colspan="10"></tablehead></tablerow><tablerow><tablecell colspan="2"><bold>Adderall</bold>#tag:ref</tablecell><tablecell></tablecell><tablecell></tablecell><tablecell></tablecell><tablecell><xhtml:center>62.6%</xhtml:center></tablecell><tablecell><xhtml:center>47.5%</xhtml:center></tablecell><tablecell><xhtml:center>15.1%</xhtml:center></tablecell><tablecell><xhtml:center>14.2&amp;nbsp;mg</xhtml:center></tablecell><tablecell><xhtml:center>4.5&amp;nbsp;mg</xhtml:center></tablecell></tablerow><tablerow><tablecell>25%</tablecell><tablecell>dextroamphetamine sulfate<extension extension_name='ref' name="damph1"></extension><extension extension_name='ref' name="damph2"></extension></tablecell><tablecell>(C<xhtml:sub>9</xhtml:sub>H<xhtml:sub>13</xhtml:sub>N)<xhtml:sub>2</xhtml:sub><template><target>bull</target></template>H<xhtml:sub>2</xhtml:sub>SO<xhtml:sub>4</xhtml:sub></tablecell><tablecell><xhtml:center>368.49</xhtml:center></tablecell><tablecell><xhtml:center>270.41</xhtml:center></tablecell><tablecell><xhtml:center>73.4%</xhtml:center></tablecell><tablecell><xhtml:center>73.4%</xhtml:center></tablecell><tablecell><xhtml:center></xhtml:center></tablecell><tablecell></tablecell><tablecell></tablecell></tablerow><tablerow><tablecell>25%</tablecell><tablecell>amphetamine sulfate<extension extension_name='ref' name="Amph sulfate mass"><template><target>Cite web</target><arg name="date"><space/>March 2014<space/></arg><arg name="title"><space/>Amphetamine Sulfate USP<space/></arg><arg name="publisher"><space/>Mallinckrodt Pharmaceuticals<space/></arg><arg name="url">http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id</arg><arg name="accessdate"><space/>19 August 2015<space/></arg></template></extension></tablecell><tablecell>(C<xhtml:sub>9</xhtml:sub>H<xhtml:sub>13</xhtml:sub>N)<xhtml:sub>2</xhtml:sub><template><target>bull</target></template>H<xhtml:sub>2</xhtml:sub>SO<xhtml:sub>4</xhtml:sub></tablecell><tablecell><xhtml:center>368.49</xhtml:center></tablecell><tablecell><xhtml:center>270.41</xhtml:center></tablecell><tablecell><xhtml:center>73.4%</xhtml:center></tablecell><tablecell><xhtml:center>36.7%</xhtml:center></tablecell><tablecell><xhtml:center>36.7%</xhtml:center></tablecell><tablecell></tablecell><tablecell></tablecell></tablerow><tablerow><tablecell>25%</tablecell><tablecell>dextroamphetamine saccharate<extension extension_name='ref'><template><target>Cite web</target><arg name="date"><space/>March 2014<space/></arg><arg name="title"><space/>Dextroamphetamine Saccharate<space/></arg><arg name="publisher"><space/>Mallinckrodt Pharmaceuticals<space/></arg><arg name="url">http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id</arg><arg name="accessdate"><space/>19 August 2015<space/></arg></template></extension></tablecell><tablecell>(C<xhtml:sub>9</xhtml:sub>H<xhtml:sub>13</xhtml:sub>N)<xhtml:sub>2</xhtml:sub><template><target>bull</target></template>C<xhtml:sub>6</xhtml:sub>H<xhtml:sub>10</xhtml:sub>O<xhtml:sub>8</xhtml:sub></tablecell><tablecell><xhtml:center>480.55</xhtml:center></tablecell><tablecell><xhtml:center>270.41</xhtml:center></tablecell><tablecell><xhtml:center>56.3%</xhtml:center></tablecell><tablecell><xhtml:center>56.3%</xhtml:center></tablecell><tablecell><xhtml:center></xhtml:center></tablecell><tablecell></tablecell><tablecell></tablecell></tablerow><tablerow><tablecell>25%</tablecell><tablecell>amphetamine aspartate monohydrate<extension extension_name='ref'><template><target>Cite web</target><arg name="date"><space/>March 2014<space/></arg><arg name="title"><space/>Amphetamine Aspartate<space/></arg><arg name="publisher"><space/>Mallinckrodt Pharmaceuticals<space/></arg><arg name="url">http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id</arg><arg name="accessdate"><space/>19 August 2015<space/></arg></template></extension></tablecell><tablecell>(C<xhtml:sub>9</xhtml:sub>H<xhtml:sub>13</xhtml:sub>N)<template><target>bull</target></template>C<xhtml:sub>4</xhtml:sub>H<xhtml:sub>7</xhtml:sub>NO<xhtml:sub>4</xhtml:sub><template><target>bull</target></template>H<xhtml:sub>2</xhtml:sub>O</tablecell><tablecell><xhtml:center>286.32</xhtml:center></tablecell><tablecell><xhtml:center>135.21</xhtml:center></tablecell><tablecell><xhtml:center>47.2%</xhtml:center></tablecell><tablecell><xhtml:center>23.6%</xhtml:center></tablecell><tablecell><xhtml:center>23.6%</xhtml:center></tablecell><tablecell></tablecell><tablecell></tablecell></tablerow><tablerow><tablehead colspan="10"></tablehead></tablerow><tablerow><tablecell colspan="2"><bold>lisdexamfetamine dimesylate</bold><extension extension_name='ref' name="FDA Vyvanse"></extension></tablecell><tablecell>C<xhtml:sub>15</xhtml:sub>H<xhtml:sub>25</xhtml:sub>N<xhtml:sub>3</xhtml:sub>O<template><target>bull</target></template>(CH<xhtml:sub>4</xhtml:sub>O<xhtml:sub>3</xhtml:sub>S)<xhtml:sub>2</xhtml:sub></tablecell><tablecell><xhtml:center>455.49</xhtml:center></tablecell><tablecell><xhtml:center>135.21</xhtml:center></tablecell><tablecell><xhtml:center>29.7%</xhtml:center></tablecell><tablecell><xhtml:center>29.7%</xhtml:center></tablecell><tablecell><xhtml:center></xhtml:center></tablecell><tablecell><xhtml:center>8.9&amp;nbsp;mg</xhtml:center></tablecell><tablecell><xhtml:center></xhtml:center></tablecell></tablerow></table>==Notes==</preline><preline><template><target>reflist</target><arg name="group">note</arg></template></preline></preblock><list type='def'><listitem><defkey>Image legend</defkey></listitem></list><paragraph><template><target>reflist</target><arg name="group">Color legend</arg></template></paragraph><heading level='2'>Reference notes</heading><paragraph><template><target>reflist</target><arg name="group">sources</arg><arg>33em</arg></template></paragraph><heading level='2'>References</heading><paragraph><template><target>reflist</target><arg>33em</arg></template></paragraph><heading level='2'>External links</heading><preblock><preline><template><target>Commons</target><arg>Amphetamine</arg></template></preline></preblock><paragraph><template><target>Commons category</target><arg>Amphetamine</arg><arg>Category:Amphetamine</arg></template></paragraph><preblock><preline>*<space/><template><target>PubChemLink</target><arg>3007</arg></template>&amp;nbsp; Amphetamine</preline></preblock><list type='bullet'><listitem><template><target>PubChemLink</target><arg>5826</arg></template>&amp;nbsp; Dextroamphetamine</listitem><listitem><template><target>PubChemLink</target><arg>32893</arg></template>&amp;nbsp; Levoamphetamine</listitem><listitem><link type='external' href='http://ctdbase.org/query.go?type=ixn&amp;amp;chemqt=equals&amp;amp;chem=name%3AAmphetamine&amp;amp;actionDegreeTypes=increases&amp;amp;actionDegreeTypes=decreases&amp;amp;actionDegreeTypes=affects&amp;amp;actionTypes=ANY&amp;amp;geneqt=equals&amp;amp;gene=&amp;amp;pathwayqt=equals&amp;amp;pathway=&amp;amp;taxonqt=equals&amp;amp;taxon=TAXON%3A9606&amp;amp;goqt=equals&amp;amp;go=&amp;amp;sort=chemNmSort&amp;amp;perPage=500&amp;amp;action=Search'>Comparative Toxicogenomics Database entry: Amphetamine</link></listitem><listitem><link type='external' href='http://ctdbase.org/detail.go?type=gene&amp;amp;acc=9607&amp;amp;qid=2119242'>Comparative Toxicogenomics Database entry: CARTPT</link></listitem></list><preblock><preline><template><target>Amphetamine</target><arg name="state">expanded</arg></template></preline></preblock><paragraph><template><target>Methamphetamine</target></template><template><target>ADHD pharmacotherapies</target></template><template><target>Phenethylamines</target></template><template><target>TAAR ligands</target></template></paragraph><preblock><preline><template><target>Portal bar</target><arg>Pharmacology</arg><arg>Medicine</arg><arg>Chemistry</arg><arg>Neuroscience</arg><arg>Molecular and cellular biology</arg></template></preline></preblock><preblock><preline><link><target>Category:Amphetamine</target><part></part></link></preline></preblock><paragraph><link><target>Category:Anorectics</target></link><link><target>Category:Drugs acting on the cardiovascular system</target></link><link><target>Category:Drugs acting on the nervous system</target></link><link><target>Category:Drugs in sport</target></link><link><target>Category:Euphoriants</target></link><link><target>Category:Excitatory amino acid reuptake inhibitors</target></link><link><target>Category:German inventions</target></link><link><target>Category:5-HT1A agonists</target></link><link><target>Category:Management of obesity</target></link><link><target>Category:Narcolepsy</target></link><link><target>Category:Nootropics</target></link><link><target>Category:Norepinephrine-dopamine releasing agents</target></link><link><target>Category:Phenethylamines</target></link><link><target>Category:Stimulants</target></link><link><target>Category:Substituted amphetamines</target></link><link><target>Category:TAAR1 agonists</target></link><link><target>Category:Treatment and management of attention deficit hyperactivity disorder</target></link><link><target>Category:VMAT inhibitors</target></link></paragraph></article>